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CHAPTER I 
 
 INTRODUCTION TO SIGNALING PATHWAYS IMPLICATED IN INTESTINAL 
HOMEOSTASIS AND INTESTINAL TUMOR DEVELOPMENT 
 
Intestinal Epithelium Biology 
 The intestinal tract, simply put, is a muscular tube lined by a single layer of 
epithelium which is highly dynamic and has multiple functions. Within the digestive tract, 
the intestinal epithelium has unique absorptive functions as well as important barrier 
functions, forming the interface between the host and external environment. In order to 
simultaneously accomplish both absorptive and barrier functions, the intestine maintains 
a simple columnar epithelium with specialized apical and baso-lateral cellular structures 
for each task. Intestinal crypt/villus architecture is maintained in a dynamic homeostasis 
sustained by stem cells residing in the crypt which produce daughter cells that migrate 
toward the luminal aspect of the tract before being shed into the lumen after undergoing 
apoptosis/anoikis (Grossmann, Walther et al. 2002) (Figure 1.1A,B). By this process, 
most of the differentiated intestinal epithelium is replaced every 5-7 days from the stem 
cell compartment (Creamer, Shorter et al. 1961).  While transiting the crypt/villus axis 
toward the intestinal lumen, cells pass through a transient proliferative compartment 
before differentiating into specialized enterocytes (absorptive), goblet, tuft, Paneth, 
enteroendocrine, microfold, and cup cells (Figure 1.1 A,B; tuft, microfold, and cup cells 
not depicted). A delicate balance must be maintained between the proliferative aspect of 
the intestinal crypt to replace cells being shed into the lumen and the differentiation 
aspect of the crypt which permits cells to perform their proper function in order to 
maintain homeostasis.  
  Reflecting function, the architecture of the intestinal tract varies significantly. The 
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proximal aspect of the small intestine (duodenum) is highly specialized for absorptive 
function reflected in the prominence of villi and microvilli structures that increase the  
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absorptive surface area. Toward the more distal aspect of the small intestine (ileum), 
where absorptive need is reduced, villus structures are shorter and surface area is 
reduced. The architecture of the large intestine, which functions to re-absorb water, 
concentrate fecal material and lubricate feces, to prevent mechanical damage, lacks 
villus projections altogether (Figure 1.1A,B). 
   The cellular architecture of the intestinal crypt/villus is governed by specific 
signals triggered by positional cues arising from adjacent epithelial cells and from the 
adjacent tissue stroma. The central signaling pathway in determining cell fate decisions 
in the crypt is Notch signaling (discussed in greater detail below). Activation of Notch 
signaling within the intestinal tract directs a cell to differentiate into the absorptive 
enterocytes over the secretory lineage (Fre, Huyghe et al. 2005, Gerbe, van Es et al. 
2011); whereas, inhibition of Notch signaling leads to secretory cell hyperplasia within 
the intestinal crypt (van Es, van Gijn et al. 2005). Enterocytes are the main absorptive 
cells; they function to absorb nutrients (ions, vitamins, amino acids, carbohydrates, and 
lipids) from the intestinal lumen, to secrete immunoglobulins, and to act as a barrier, and 
they comprise the majority of epithelial cells within the intestinal crypt. Goblet cells are 
found throughout the small and large intestine and function in secreting mucins that 
create a mucinous barrier within the intestinal tract to protect epithelial from microbial 
insult and mechanical stress (Specian and Oliver 1991). Goblet cells can be identified by 
expression of mucins (Muc2, etc.), Periodic Acid-Schiff (PAS) or Alcian blue stains 
(Takeyama, Dabbagh et al. 1999). Enteroendocrine cells are identified by expression of 
chromagranin A and secrete hormones and signaling molecules such as gastrin, ghrelin, 
somatostatin, cholecystokinin, serotonin, glucose-dependent insulinotropic peptide, 
glucagon-like peptides, and peptide YY (Moran, Leslie et al. 2008).  Paneth cells are 
found strictly in the small intestine and appendix at the base of the crypt-villus axis, are 
marked by CD24, and unlike the other  differentiated cells of the epithelium, remain in 
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the crypt for approximately three weeks (Garabedian, Roberts et al. 1997, Sato, van Es 
et al. 2011). Paneth cells function in the maintenance of stem cell niche as well as 
protecting the crypt base from microbial insult by secretion of anti-microbial peptides 
(such as crytidin-1 and lysozyme) (Ayabe, Satchell et al. 2000, Porter, Bevins et al. 
2002). Tuft cells comprise relatively few of the epithelial cells within the intestinal tract 
(~0.5%) and their precise function is still not known (Gerbe, Legraverend et al. 2012). 
They can be identified by their expression of cytokeratin 18 and DCLK1 though the latter 
marker also marks a subset of enteroendocrine cells and quiescent stem cells (Hofer 
and Drenckhahn 1996, Gerbe, van Es et al. 2011). Microfold cells (M cells) are 
specialized epithelium that with enterocytes overlay gut-associated lymphoid tissues 
(GALTs), and permit transcytosis of antigens and microorganisms and present them to 
the underlying lymphoid tissue (Nicoletti 2000). M cells are stimulated by RANKL and 
identified by their expression of UEA-1, annexin V, SpiB, and GP2 expression and also 
express vimentin (de Lau, Kujala et al. 2012). Cup cells are  limited mostly to the ileum 
of the small intestine and are characterized by shorter brush border, markedly weaker 
alkaline phosphatase expression compared to enterocytes and express vimentin like M 
cells though they do not present antigens to lymphoid tissue (Madara 1982, Fujimura 
and Iida 2001, Gerbe, Legraverend et al. 2012). 
Intestinal Stem Cells 
  Within the intestinal epithelium, stem cells constantly undergo asymmetrical 
division to repopulate the differentiated epithelium while simultaneously maintaining the 
stem cell niche. Within the small intestine, there are data to support the existence of two 
separate stem cell populations: the columnar base cells wedged between Paneth cells 
that undergo steady division within the crypt and the +4 position stem cells that remain 
quiescent until a stimulus, such as injury, occurs signaling entry into the cell cycle 
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(Barker, van de Wetering et al. 2008). The stem cell niche within the large intestine is 
maintained at the base of the crypt. In order to identify stem cell markers, a number of 
long term lineage tracing studies have been performed, and though there are differences 
in the architecture of small and large intestine stem cell niche, there are some similarities 
in some of the markers identified. For instance, steadily dividing stem cells are marked 
by Lgr5 expression (Barker, van Es et al. 2007) and the cells that replace the epithelium 
upon injury are marked by Lrig1, Bmi-1, and mTert expression (Sangiorgi and Capecchi 
2008, Montgomery, Carlone et al. 2011, Tian, Biehs et al. 2011, Powell, Wang et al. 
2012). There are also similarities in the signaling pathways at work between the small 
and large intestine to maintain the stem cell niche. 
Wnt signaling  
  The main signaling pathway implicated in maintenance of the stem cell niche 
within the intestinal tract is canonical Wnt signaling (Reya and Clevers 2005, Fevr, 
Robine et al. 2007). The Wnt signaling pathway was first described in the 1980’s and 
derived its name from the high degree of conservation that Drosophila gene Wingless 
and murine  Int-1 shared (Wg  + Int-1 = Wnt) (Nusse and Varmus 1982, Rijsewijk, 
Schuermann et al. 1987). β-Catenin is the central mediator of canonical Wnt signaling 
and is localized to the cell membrane at the adherens junction through its interaction 
with E-cadherin (Figure 1.2A) (Logan and Nusse 2004). However, whenever β-Catenin 
dissociates from the cell membrane and accumulates in the cytoplasm, it is targeted for 
proteasomal degradation through a protein degradation complex consisting of Axin, 
adenomatous polyposis coli (APC), casein kinase 1α (CK1α), glycogen synthase kinase 
3β (GSK3β). Whenever a Wnt ligand is present, it binds to the Lrp5/6 receptor and 
Frizzled on the cell membrane and is thought to sequester Axin away from the 
degradation complex, thereby, allowing cytoplasmic levels of β-catenin to increase. β-  
 6 
 
 
Gene  Function Direct target? Reference(s) 
c-Myc Transcription factor responding 
to mitogenic stimuli 
Tcf/Lef binding sites 
within promoter  
He, et al, 1998 
(He, Sparks et al. 
1998) 
Cyclin D1 Cell cycle regulation Tcf/Lef1 site within 
promoter 
Shtutman, et al, 
1999 (Shtutman, 
Zhurinsky et al. 
1999) 
Axin2 Negative regulator of Wnt 
Signaling 
Tcf/Lef sit within 
promoter 
Jho, et al, 
2002(Jho, Zhang 
et al. 2002) 
Ascl2 Proliferation in Trophoblast 
during development (Guillemot, 
Nagy et al. 1994) 
Expression down with 
expression of Lef1 
dominant negative  
Jubb et al, 2006 
(Jubb, Chalasani 
et al. 2006) 
Lgr5 Unknown, co-internalizes with 
LRP6 on Wnt binding (Carmon, 
Lin et al. 2012), putative R-
spondin receptor (de Lau, 
Barker et al. 2011) 
Expression ablated upon 
expression of dominant 
negative Tcf4 
Barker et al, 
2007(Barker, van 
Es et al. 2007) 
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catenin then translocates to the nucleus, displaces the transcriptional suppressor, 
Groucho, from T cell specific transcription factor/Lymphoid enhancer-binding factor 1 
(TCF/LEF) and drives a specific transcriptional program (Figure 1.2B). Many canonical 
Wnt targets, genes which change expression upon activation of Wnt signaling, have 
been elucidated over the years (Table 1). Axin2, Cyclin D1, c-Myc, and Ascl2 have been 
shown to be under transcriptional control by TCF/LEF and have frequently been used as 
experimental markers to establish whether and where Wnt signaling is occurring within 
the intestinal tract in various disease states.    
 Within the intestinal tract, Wnt signaling is greatest toward the base of the crypt 
where it is required to maintain the intestinal stem cell niche. Within the small intestine, 
Paneth cells supply a source of Wnt ligands, predominantly Wnt3 and 11, while in the 
large intestine, CD24+ positive cells residing between Lgr5+ cells may also function as a 
source for Wnt ligand (Sato, van Es et al. 2011). In addition, Wnt signaling can be 
influenced by other factors such as R-spondin which functions to enhance Wnt signaling, 
but R-spondin cannot activate Wnt signaling on its own (Glinka, Dolde et al. 2011, de 
Lau, Snel et al. 2012).Mesenchymal cells surrounding the crypt have been implicated in 
an antagonistic role to Wnt signaling through secretion of Wnt antagonists (SFRP-1, 
SFRP-2, Dkk-2 and Dkk-3) ensuring that the stem cell niche is maintained toward the 
base of the crypt (Pinchuk, Mifflin et al. 2010). Nuclear localization of β-Catenin 
visualized by immunohistochemistry is also observed toward the base of the crypt (van 
de Wetering, Sancho et al. 2002). Active Wnt signaling is necessary for maintenance of 
normal intestinal homeostasis and proliferative zone (Fevr, Robine et al. 2007). 
TGF-β Family Signaling 
 
            The TGF-β family of ligands is a broad series of developmentally critical growth 
factors and morphogens including Transforming Growth Factor βs (TGF-βs), Activins,  
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Nodals, Bone morphogenic proteins (BMPs),  Growth and Differentiation Factors 
(GDFs), Mullerian Inhibiting Substance (MIS) (Shi and Massague 2003). For the purpose 
of this work, we will focus our discussion upon TGF-βs and BMPs. All major branches of 
TGF-β family act through ligand binding to a heteromeric complex of ligand-specific type 
1 (Alk1-7) and type II serine/threonine kinase receptors (Shi and Massague 2003).  
Ligand binding to specific type II receptors results in formation of the heteromeric 
complex with type I receptors. This leads to a phosphorylation of the type I receptor, 
initiating a phosphorylating cascade sequence into one of two major branches of the 
Smad signaling pathway through phosphorylation of Receptor Associated Smads (R-
Smads), which are enumerated Smads1-3, 5 and 8 (Shi and Massague 2003). Smads 
1,5, and 8 function to transduce signals for the BMPs and their specific  type II (BMPR-
II,ActR-II/B) and type I  receptors (Alk3, Alk6, and Alk2) receptors while Smads 2 and 3 
transduce the signal for TGF-β  through type I receptor (Alk5) and TGF-β selective type 
II receptor (Figure 1.3A,B). Phosphorylated R-Smads bind to the common Smad 
mediator, Smad4, allowing them to be efficiently translocated to the cell nucleus (Figure 
1.3A,B).  Smad nuclear complexes interact with specific consensus Smad DNA binding 
elements and other co-transcription factors regulating the expression of specific target 
genes, depending on the context (Massague 2008).       
              There are multiple levels of regulation that occur within the TGF-β signaling 
pathway. Ligand binding to type II receptors is regulated by a family of proteins known 
as ligand traps, which can specifically bind to ligands blocking their access to receptors. 
For example, Noggin entraps BMPs 2, 4, and 7 and inhibits activation of the type II 
receptors (Hirsinger, Duprez et al. 1997, Marcelino, Sciortino et al. 2001). Inhibitory 
Smads (Smads 6,7) inhibit signaling by interfering with the R-Smads. Smad7 can inhibit 
both TGF-β and BMP signaling pathway while Smad6 inhibits BMP signaling 
preferentially (Nakao, Afrakhte et al. 1997, Hata, Lagna et al. 1998). Ubiquitylation and  
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proteasomal degradation regulate the steady-state levels of the Smad proteins 
(Massague, Seoane et al. 2005). 
              Within the epithelium of the intestinal tract, the TGF-β family of peptides inhibits 
mitotic activity. This activity was first noted when treatment of cultured rat intestinal 
epithelial cells with TGF-β resulted in inhibition of incorporation of [3H]-thymidine  and 
increased expression of sucrase suggesting both an inhibition of mitosis and promotion 
of functional differentiated cells (Kurokowa, Lynch et al. 1987).  In vitro TGF-β treatment 
resulted in G1 cell cycle arrest, associated with down-regulation of Cyclin D1, and 
inhibition of Cdk4 kinase activity (Ko, Sheng et al. 1995, Ko, Yu et al. 1998). As intestinal 
epithelial cells migrate toward the luminal aspect of the crypt, there is increased 
expression of TGF-β1 and type II TGF-β receptor (Barnard, Beauchamp et al. 1989, 
Barnard, Warwick et al. 1993, Winesett, Ramsey et al. 1996). This expression pattern is 
inversely correlated with proliferation within the intestinal epithelium (Figure 1.4) (Zhang, 
Nanney et al. 1997). Within normal intestinal epithelium, BMP is a major driver of 
differentiation and apoptosis toward the luminal aspect of the intestinal crypt and is 
thought to inhibit Wnt signaling (Kosinski, Li et al. 2007, Brabletz, Schmalhofer et al. 
2009). In vitro treatment with BMP-2 promotes apoptosis and growth inhibition in colon 
cancer cell lines (Hardwick, Van Den Brink et al. 2004). Within the intestinal crypt, 
antagonists to BMP signaling Grem1 and Grem2, and Chordin-like1 are expressed 
toward the base of the crypt (Figure 1.4) (Kosinski, Li et al. 2007), and transgenic mice 
expressing Noggin, a BMP antagonist, aberrantly develop crypts perpendicular to the 
normal crypt-villous axis (Haramis, Begthel et al. 2004). Taken together these illustrate a 
functional role for TGF-β signaling in normal homeostasis and differentiation within the 
intestinal tract. 
Non-canonical TGF-β Family Signaling 
              Non-canonical (non-Smad) TGF-β signaling also occurs in intestinal epithelial 
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cells and can influence their growth and proliferation. Treatment with exogenous TGF- β 
can lead to activation of Erk, JNK, and p38 pathways (Yue and Mulder 2000, Derynck 
and Zhang 2003, Zhang 2009). Experiments using TGF-β type I receptor mutant 
constructs show activation of p38 (Yu, Hebert et al. 2002) and Erk pathway through 
activation of Ras and lead to senescence (Cipriano, Kan et al. 2011). Activation of JNK 
pathway by TGF-β was shown to be TAK1 and TRAF6 dependent and induced 
apoptosis (Shim, Xiao et al. 2005, Yamashita, Fatyol et al. 2008). Activation of Erk and 
Jnk can in turn lead to activation of the canonical Smad pathway through 
phosphorylation of R-Smads further complicating differentiating between canonical 
versus non-canonical effects of TGF-β treatment (Engel, McDonnell et al. 1999, 
Hayashida, Decaestecker et al. 2003, Hough, Radu et al. 2012, Liu, Zhang et al. 2012). 
Conditional knockout of BMP Receptor 1A in mice resulted in the development of 
intestinal polyps, inhibition of BMP signaling, resultant PTEN activation and increasing 
levels of pAKT in association with increased β-catenin levels (He, Zhang et al. 2004) 
again showing consequences of removing aspects of the  TGF-β signaling pathway can 
lead to aberrant non-canonical signaling. 
Other Signaling Pathways Implicated in Intestinal Homeostasis 
            The Notch signaling pathway has been implicated in cell fate decisions and 
differentiation (Radtke and Clevers 2005, van Es, van Gijn et al. 2005). Notch signaling 
functions through cleavage of the Notch receptor by proteolytic proteins upon binding to 
any of the Delta, Serrate, or JAG2 ligands expressed on adjacent cells (Guruharsha, 
Kankel et al. 2012). This releases the Notch intracellular domain (NICD) into the cytosol. 
NICD translocates to the nucleus and interacts with the transcription factor RBPJ to 
express Hes1 (VanDussen, Carulli et al. 2012) and suppresses the expression of atonal  
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homologue 1 (Atoh1) (Yang, Bermingham et al. 2001, Shroyer, Helmrath et al. 2007, 
VanDussen and Samuelson 2010) (Figure 1.5A).  Again, activation of Notch signaling 
within intestinal epithelium leads to development into absorptive enterocytes. However, 
in the absence of Notch activation, Atoh1 drives the differentiation down the secretory 
lineage (Yang, Bermingham et al. 2001) and has, for example, been shown to 
transcriptionally activate expression of goblet cell marker Muc2 (Park, Oh et al. 2006).   
              The epidermal growth factor (EGF) signaling pathway has been implicated in 
proliferation and maintenance of the stem cell niche (Biteau and Jasper 2011). There are 
four members of the ErbB receptor tyrosine kinase: Her1 (EGFR, ErbB1), Her2 
(Neu, ErbB2), Her3 (ErbB3), and Her4 (ErbB4) that can combine together in 
homodimers or heterodimers to transduce signal upon binding to one of the eleven 
known ligands including EGF and transforming growth factor alpha (TGFα) (Garrett, 
McKern et al. 2002, Linggi and Carpenter 2006). This dimerization leads to 
phosphorylation of the C-terminal domain of the receptor allowing for a cascade of 
phosphorylation of several proteins that have an SH2 binding domain leading to 
activation of several downstream signaling pathways including: MAPK, PI3K, STAT, and 
other pathways. The end result of this activation leads to cellular growth and progression 
through the cell cycle  (Oda, Matsuoka et al. 2005) (Figure 1.5B). 
             Hedgehog (Hh) signaling is mediated by a transmembrane protein Patched1 
(Ptch1) which, without hedgehog ligand, suppresses another transmembrane protein  
Smoothen (Smo). Upon hedgehog ligand binding to Ptch1, the suppression of Smo is 
removed permitting Smo to activate Gliomas (Gli’s) for signal transduction (Parkin and 
Ingham 2008) (Figure 1.5C). Though Indian hedgehog (Ihh) is expressed within 
intestinal epithelium, most of Hedgehog signal activation is restricted to the 
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mesenchyme (Kolterud, Grosse et al. 2009, van Dop, Heijmans et al. 2010). Interference 
with this pathway leads increased Wnt signaling and improper maturation of intestinal 
epithelium (Wang, Nassir et al. 2002, van den Brink, Bleuming et al. 2004). Also, mice 
lacking hedgehog ligand expression (Ihh and Sonic hedgehog [Shh]) display decreased 
thickness in the muscular layer surrounding the intestine and malformation of the enteric 
nervous system showing that hedgehog signal is important in intestinal development and 
homeostasis (Ramalho-Santos, Melton et al. 2000). 
Interaction between the Wnt and TGF-β signaling pathways 
               As diagrammed in Figure 1.4, Wnt and TGF-β family signaling pathways occur 
in opposite gradients along the intestinal crypt; however, previous studies have 
implicated more interactions between these two pathways. As previously stated loss of 
BMP signaling can lead to increase pAKT levels (61) which in turn can inhibit GSK3 
activity resulting in increased levels of β-catenin protein (Cross, Alessi et al. 1995, He, 
Zhang et al. 2004). Further, Ihh knockout mice lose mesenchymal expression of BMP 
ligands associated with an extension of the proliferative zone (Kosinski, Stange et al. 
2010); though, a later study suggests that loss of activin expression, not BMP, is 
responsible for this proliferative zone expansion (Buller, Rosekrans et al. 2012). In 
Xenopus, direct interaction between the Smads and β-catenin and TCF/Lef1 have been 
observed within the Spemann’s organizer to promote the expression of Xtwn, the 
Xenopus ortholog of human KLF5/BTEB2. KLF5 functions in the suppression of 
proliferation in non-transformed intestinal epithelium and is seen to be down regulated in 
colorectal cancer cases (Labbe, Letamendia et al. 2000, Nishita, Hashimoto et al. 2000, 
Bateman, Tan et al. 2004). Other investigators have reported that TGF-β3 stimulates 
transcription of LEF-1 that in turn interacts with Smad2 and Smad4 to inhibit E-cadherin 
in palate medial epithelium (Nawshad, Medici et al. 2007). Another group reported 
identification of a complex between β-catenin and Smad2 in alveolar epithelium upon 
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injury (Kim, Wei et al. 2009). However, a transcriptional regulation of β-catenin by 
Smad4 signaling had not been described prior to our report in 2012 (Freeman, Smith et 
al. 2012). 
Applications of Stem Cell Biology  
  Enteroid Culture - Utilizing the known pathways for maintenance of the stem cell 
niche as well as the knowledge of the signals that are required to stimulate 
differentiation, researchers have developed in vitro culture techniques in which enteroids 
derived from both mouse and human intestinal crypts can be established (Sato, Vries et 
al. 2009). Enteroids refer to establishing three dimensional cultures using artificial 
extracellular matrix substrates (such as commercially available “matrigel”) that permit the 
growth and differentiation of epithelium derived solely from the small intestine (Stelzner, 
Helmrath et al. 2012). Essentially, this technique depends upon isolation of intact crypt 
bases and the use of media containing EGF, to stimulate cells to grow and proliferate, R-
spondin, a Wnt agonist to stimulate Wnt pathway activation, and Noggin, a BMP ligand 
trap to prevent differentiation within the culture. This technique has provided an in vitro 
avenue to study differentiation of the intestinal epithelium without contamination of the 
stromal component allowing for powerful analysis on dissecting how gene manipulations 
alter signaling in the context of epithelial homeostasis.  
  Colorectal Cancer – Two of the hallmarks of cancer  are sustained proliferative 
signaling and evasion of growth repressors (Hanahan and Weinberg 2011), so it is not 
surprising that colorectal carcinomas have an expression pattern that resembles 
intestinal stem cell niche (Merlos-Suarez, Barriga et al. 2011). As discussed, activation 
of the Wnt pathway stimulates the proliferation within the intestinal tract, and the Wnt 
pathway is dysregulated in the vast majority of colorectal cancer (discussed in greater 
detail below). Immunohistochemical evidence of increased Wnt pathway activation as 
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indicated by increased nuclear localization of β-catenin has been reported at the 
invasive edge of colorectal cancers (Brabletz, Jung et al. 2001). Moreover, experiments 
using primary human colorectal cancer cells found that cells with high level of Wnt 
pathway activation function as the cancer stem cell (Vermeulen, De Sousa et al.).  
Further,  stem cell markers (such as Lgr5, a target of canonical Wnt signaling) have 
been used to define a non-transformed intestinal stem cell gene signature that can be 
used to predict more aggressive disease with greater chance of recurrence in human 
colorectal tumors with a similar expression pattern (Merlos-Suarez, Barriga et al. 2011). 
Colon cancer stem cells are thought to be needed to establish metastases and represent 
a niche often refractory to standard therapy (Pang, Law et al. 2010, Todaro, Francipane 
et al. 2010). Thus, understanding the normal intestinal development and regulation of 
those pathways is paramount in investigating the molecular underpinnings of colorectal 
cancer. 
Epidemiology and Pathogenesis of Sporadic Colorectal Cancer 
 Colorectal cancer is projected to be the third leading cause of cancer related 
mortality in the United States in 2014 with approximately 50,000 individuals succumbing 
to this disease each year and another 150,000 patients will be newly diagnosed (Siegel, 
Naishadham et al. 2013). The vast majority (>90%) of cases are diagnosed in patients 
greater than 50 years of age and are thought to occur due to gradual accumulation of 
mutations over time (Hawk and Levin 2005, Cress, Morris et al. 2006, Siegel, 
Naishadham et al. 2013). While increased surveillance by colonoscopy, greater usage of 
NSAIDS, and improved therapies have purportedly reduced mortality since the 1980’s 
(Fearon 2011) , the five year survival rate  for patients diagnosed with  stage IV disease 
remains low (12.9%) (Edge and Compton 2010). While local tumor growth can lead to 
organ dysfunction and death, 90% of cancer related deaths are attributed to metastatic  
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disease (Hanahan and Weinberg 2000, Gupta and Massague 2006). The process of 
metastasis depends upon a cancer cell’s potential to invade neighboring tissue, access 
vascular or lymphatic vessels, survive dissemination and extravasate to establish 
residence in distant organs and tissues. Therefore, understanding the signaling required 
and regulators of the metastatic process is essential in combating cancer mortality. 
  In sporadic colorectal cancer, mutations are thought to accumulate in a 
stochastic manner over time with the key gatekeeper mutation occurring in APC (Figure 
1.6) (Fearon and Vogelstein 1990). APC functions as a suppressor of the Wnt signaling 
pathway via the degradation of cytoplasmic β-catenin (Figure 1. 2). Whenever APC is 
mutationally inactivated, inappropriate accumulation of cytoplasmic β-catenin leading to 
activation of the Wnt pathway within the colonic crypt occurs. Mutational inactivation of 
APC occurs in approximately 80% of all colorectal cancer cases (Fearon 2011) while 
another 5% of cases have activating mutations in β-catenin (Fearon 2011) that prevent 
β-catenin degradation by the proteasomal degradation complex. A small number of 
cancers exhibit translocations in  R-spondin2 leading to overexpression and increase 
Wnt pathway activation (Seshagiri, Stawiski et al. 2012). All of these mutations thus lead 
to overexpression of Wnt targets such c-Myc and Cyclin D1 which promote cell cycle 
transit. 
 As lesions continue to accumulate mutations, activation mutations and loss of 
tumor suppressors within other pathways can also transpire (Figure 1.6). Mutations in 
Ras or BRAF occur in 30-40% of colorectal cancer cases (Bos, Fearon et al. 1987, 
Davies, Bignell et al. 2002, Fearon 2011) and lead to activation of mitogen activated 
kinase signaling pathway. Mutations in Ras are thought to occur early on in disease 
progression and lead to development of adenomatous lesions in the background of Wnt 
pathway activation (Pretlow and Pretlow 2005).  TP53 mutation prevents p53’s normal 
function in mediating cell cycle arrest and apoptosis checkpoint (Vazquez, Bond et al. 
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2008, Vousden and Prives 2009). Loss of heterozygosity, chromosomal deletion of a 
gene and surrounding area, and missense mutation of the other allele of p53 is thought 
to occur in up to 70% of colorectal cancer cases (Vogelstein, Fearon et al. 1988). 
Activation mutations in PI3K pathway occur in 25% (Samuels, Wang et al. 2004) of 
cases while inactivation of PTEN occurs in approximately 20% (Laurent-Puig, Cayre et 
al. 2009). Though the PI3K pathway is downstream of Ras signaling it is thought that 
activation of the pathway by Ras mutation alone may be inefficient (Li, Zhu et al. 2004).  
Although these pathways play key roles in the pathogenesis of colorectal cancer, in 
depth study of their function falls outside the scope of this work and will not be 
discussed. 
TGF-β signaling in Colorectal Cancer 
  A majority of late stage colorectal cancer cases have aberrations within the TGF-
β signaling pathway (Fearon 2011). Treating adenomas with exogenous TGF-β showed 
a similar mitotic inhibition as treating non-transformed epithelium with TGF-β. However, 
treatment of adenocarcinoma with TGF-β shows a decreased response to growth 
inhibition (Manning, Williams et al. 1991). Furthermore, a direct correlation between 
sensitivity to TGF-β growth inhibition and tumor cell differentiation state has been found, 
using  human colorectal carcinoma cell lines (Hoosein, McKnight et al. 1989). Loss of 
this growth inhibitory response to TGF-β associates with malignant transformation in 
other cancer types such as breast and retinoblastoma, as well (Arteaga, Tandon et al. 
1988, Kimchi, Wang et al. 1988, Sun, Wu et al. 1994).   
  One mechanism by which this loss of sensitivity to TGF-β treatment can occur is 
through down-regulation or mutation in TGF-β receptor II. Loss of function  mutations in 
the TGF-β receptor II in colorectal cancer occur in the majority of tumors that exhibit the 
microsatellite instability/replication error phenotype that make up 13% of colorectal 
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cancer cases (Markowitz, Wang et al. 1995). This subset of colorectal cancer cases 
tends to have better prognosis than other types of sporadic colorectal cancers and tends 
to have lesions within the proximal colon (Thibodeau, Bren et al. 1993, Gryfe, Kim et al. 
2000). Mutations and loss of expression of Smad signal transduction protein can also 
contribute to tumor development and/or progression within the gastrointestinal tract 
(Elliott and Blobe 2005). Smad2 mutations have been identified in less than 10% of 
colorectal cancers (Eppert, Scherer et al. 1996, Ohtaki, Yamaguchi et al. 2001) while 
Smad3 is down-regulated in 37% of gastric carcinomas (Han, Kim et al. 2004). 
   Loss of function mutations of Smad4 occur in 20-30% of colorectal cancer 
cases, much more frequently than other Smads, (Thiagalingam, Lengauer et al. 1996, 
Riggins, Kinzler et al. 1997) and are thought to arise in the advanced adenomatous 
polyp stage of tumor progression (Rowan, Halford et al. 2005, Lassmann, Weis et al. 
2007). Loss of Smad4 has been associated with decreased levels of E-cadherin, 
development of liver metastasis and poor prognosis in Dukes C colorectal cancer 
patients (Miyaki, Iijima et al. 1999, Reinacher-Schick, Baldus et al. 2004, Alazzouzi, 
Alhopuro et al. 2005). Loss of Smad4 expression has also been associated with 
increased incidence of lymph node metastasis (Tanaka, Watanabe et al. 2008). Smad4 
(as well as BMPR1A) germline mutation is also implicated in juvenile polyposis 
syndrome, a condition which predisposes patients to developing intestinal 
adenocarcinoma (Howe, Sayed et al. 2004). This body of work focuses on how Smad4 
functions in normal intestinal homeostasis (Chapter III) and how Smad4 loss in the 
background of APC mutation affects intestinal tumorigenesis (Chapter II). 
Biological Models of Colorectal Cancer 
  In order to recapitulate human colorectal cancer pathogenesis and disease 
progression, multiple mouse models of colorectal have been developed. Several models 
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target the Apc gene due to its function in Wnt signaling and its involvement in colorectal 
cancer pathogenesis. The first of these developed, the ApcMin (Min standing for multiple 
intestinal neoplasia) model, came from a random mutagen screen perform on a mouse 
colony (Moser, Pitot et al. 1990). The result was a truncation mutant of Apc gene at 
codon 850 which resulted in the loss of regions within the protein that function in the 
binding of β-catenin. This truncation mutation, following loss of heterozygosity of the 
wild-type allele, leads to the development of approximately 100 intestinal polyps – mostly 
within the small intestine.  Development of more sophisticated genetic tools permitted 
generation of the Δ716 mutant, a truncation of Apc at codon 716, which results in 
approximately 300 small intestinal polyps (Fodde, Edelmann et al. 1994), and another 
low penetrant variant Apc1638 which has truncation at codon 1638, develops 2-3 intestinal 
polyps by six months of age, and may closely recapitulate the truncation mutation 
observed in human disease (Oshima, Oshima et al. 1995, Beroud and Soussi 1996).  
  Homozygous mutation of Smad4 in murine models are lethal in the early embryo; 
however, when a truncation of Smad4 in exon 8 was introduced on the same 
chromosome as a mutant ApcΔ716allele, the cis-compound heterozygotes produced 
larger, though less numerous, intestinal polyps than ApcΔ716 mice (Takaku, Oshima et al. 
1998). Staining of the intestinal polyps confirmed a lack of Smad4 and Apc expression. 
Unlike humans, murine Smad4 and Apc are encoded on chromosome 18, implicating 
loss of heterozygosity for both genes in intestinal carcinoma development. While 
simultaneous loss of Smad4 and Apc may explain the larger size of murine intestinal 
polyps, it is unlikely that such simultaneous loss occurs in human colorectal 
carcinogenesis. Smad4 deletion in the murine T-cell compartment results in a 
phenocopy of human Juvenile Polyposis, a syndrome predisposing patients to colorectal 
cancer development, suggesting that paracrine signaling is implicated in gastrointestinal 
epithelium homeostasis; however, reported human patient samples show Smad4 loss 
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within the epithelial compartment, not within T-lymphocytes (Kim 2006). Therefore, 
models which more closely recapitulate the pathogenesis of human colorectal cancer 
are needed to elucidate the role of Smad4 signaling in colorectal carcinoma progression.  
 In this body of work, we developed an inducible, intestinal epithelial specific 
genetic loss of Smad4 in the mouse to elucidate the role of Smad4 in normal intestinal 
homeostasis (Chapter III) and in tumor formation (Chapter II). Our work relies heavily on 
a transgenic strain established by Bardeesy et al. in 2006 generating an inducible 
truncation of Smad4 driven by Cre-recombinase.  For our studies, we generated both 
K19 CreERT2 Smad4lox/lox and Lrig1CreERT2 Smad4lox/lox (Bardeesy, Cheng et al. 2006, 
Means, Xu et al. 2008, Powell, Wang et al. 2012) compound transgenic mice that 
predictably lose expression of Smad4 specifically within the intestinal epithelium upon 
tamoxifen treatment. In this work, we have identified a previously unknown 
transcriptional regulation of the β-catenin gene (Ctnnb1) by Smad4 signaling (Chapters II 
and III) that lead to increased canonical Wnt signaling and increased tumor burden in the 
context of mutated Apc (Chapter II). In the context of non-transformed epithelium, we 
observed an increased proliferative zone and fewer numbers of enterocytes, goblet, and 
enteroendocrine cells within Smad4 null crypts compared to Smad4 expressing crypts 
using both K19 CreERT2 Smad4lox/lox and Lrig1CreERT2 Smad4lox/lox mouse models.  We 
developed Smad4 null enteroids using in vitro tamoxifen treatment and observed no 
increase in canonical Wnt targets in the Smad4 null tissue. We instead observed an 
increase in Erk activity and preliminary results points to this regulation to be associated 
with non-canonical activation of TGF-β family signaling. When crossed on the Apc1638 
background, K19 CreERT2 Smad4lox/lox have a ten-fold increase in tumor burden and 
associated increase in Wnt activity. This increase in Wnt activity is associated with 
increased levels of β-catenin mRNA supporting a previously unreported role for Smad4 
signaling in transcriptionally regulating Wnt signaling in the intestinal tract. 
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Summary 
 
  Intestinal homeostasis is critical in maintaining the delicate balance between 
proliferation to maintain the epithelial layer that is constantly being shed and 
differentiation which affords the tissue its functions of nutrient absorption and being a 
barrier. This maintenance of homeostasis requires precise signaling to transpire along 
the crypt axis. Within the intestinal tract multiple pathways have been implicated in the 
proliferation and differentiation process including the Wnt (proliferation) and TGF-β 
(differentiation) signaling pathways. In Chapter III, we describe studies showing that 
upon losing Smad4 signaling there is an increase in the number of cells within the 
proliferative zone of the large intestinal crypt accompanied by a decrease in mature 
colonocytes. We also identify a role of Smad4 in transcriptional regulation of β-catenin 
though the data suggests that in the context of non-transformed epithelium that there is 
no detectable physiological increase in Wnt signaling. Instead, in this context, we 
observe an increase in Erk activation that is possibly due to non-canonical signaling 
involving the BMP signaling pathway. 
  In the pathogenesis of colorectal cancer, many tumor suppressor pathways are 
inactivated. Most spontaneous colorectal cancers (~80%) have mutations in APC which 
permits increased Wnt/ β-catenin signaling and a majority of cases has some defect in 
TGF-β signaling critical for development and intestinal homeostasis. In Chapter II, we 
explore the regulation of β-catenin by Smad4 and describe a new role of the tumor 
suppressor Smad4 in the transcriptional repression of β-catenin. In the context of 
transformed tissue, we observe an increase of canonical Wnt signaling and observe a 
dramatic increase in tumor burden when Smad4 expression is lost. Overall, these results 
provide insight into the role of Smad4 in maintaining normal intestinal homeostasis and 
how its loss in colorectal cancer leads to tumor progression and metastasis. By 
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understanding the cellular basis for these processes, we hope to eventually learn novel 
ways to target and reverse these effects in cases in which TGF-β/BMP mediated 
signaling has been loss. 
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CHAPTER II  
 
 
 
SMAD4-MEDIATED SIGNALING INHIBITS INTESTINAL NEOPLASIA BY INHIBITING 
EXPRESSION OF β-CATENIN  
 
 
Abstract 
 Mutational inactivation of adenomatous polyposis coli (APC) is an early event in 
colorectal cancer (CRC) progression that affects the stability and increases the activity of 
β-catenin, a mediator of Wnt signaling. Progression of CRC also involves inactivation of 
signaling via transforming growth factor β and bone morphogenetic protein (BMP), which 
are tumor suppressors. However, the interactions between these pathways are not clear. 
We investigated the effects of loss of the transcription factor Smad4 on levels of β-
catenin messenger RNA (mRNA) and Wnt signaling. We used microarray analysis to 
associate levels of Smad4 and β-catenin mRNA in colorectal tumor samples from 250 
patients. We performed oligonucleotide-mediated knockdown of Smad4 in human 
embryonic kidney (HEK293T) and in HCT116 colon cancer cells and transiently 
expressed Smad4 in SW480 colon cancer cells. We analyzed adenomas from 
(APCΔ1638/+) and (APCΔ1638/+) × (K19CreERT2Smad4lox/lox) mice by using laser capture 
microdissection. 
  In human CRC samples, reduced levels of Smad4 correlated with increased 
levels of β-catenin mRNA. In Smad4-depleted cell lines, levels of β-catenin mRNA and 
Wnt signaling increased. Inhibition of BMP or depletion of Smad4 in HEK293T cells 
increased binding of RNA polymerase II to the β-catenin gene. Expression of Smad4 in 
SW480 cells reduced Wnt signaling and levels of β-catenin mRNA. In mice with 
heterozygous disruption of Apc (APCΔ1638/+), Smad4-deficient intestinal adenomas had 
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increased levels of β-catenin mRNA and expression of Wnt target genes compared with 
adenomas from APCΔ1638/+ mice that expressed Smad4.Transcription of β-catenin is 
inhibited by BMP signaling to Smad4. These findings provide important information 
about the interaction among transforming growth factor β, BMP, and Wnt signaling 
pathways in progression of CRC. 
 
Introduction 
  The central mediator of downstream Wnt signaling, β-catenin, is normally 
sequestered at the adherens junctions (E-cadherin, p120, β-catenin, α-catenin). Free 
cytoplasmic β-catenin is rapidly targeted for degradation through protein complexes that 
contain adenomatous polyposis coli (APC), Axin, and GSK3β. However, in the presence 
of Wnt ligand, GSK3β is inhibited, resulting in accumulation of cytoplasmic β-catenin. 
This increase in cytoplasmic β-catenin results in nuclear translocation of β-catenin, 
where it associates with LEF/TCF transcription factors to activate Wnt target genes 
(Clevers 2006). 
  Tight regulation of Wnt signaling within the normal intestinal tract is critical for 
maintenance of normal intestinal stem cell function and tissue homeostasis (Clevers 
2006).  Mutational inactivation of APC results in increased β-catenin protein levels with 
concomitant activation of the downstream Wnt signaling pathway and is an early event in 
progression of colorectal cancer (Kinzler and Vogelstein 1996). Inactivation of APC 
alone does not appear sufficient to fully activate Wnt signaling or to convey an invasive 
and metastatic behavior in tumor cells (Vermeulen, De Sousa et al. , Brabletz, 
Schmalhofer et al. 2009). It is likely that other mutational events or extrinsic factors may 
be necessary for maximal activation of the Wnt pathway to promote invasion and 
metastasis. Little is known about regulation of β-catenin levels outside the paradigm of 
posttranslational regulation. In particular, a role for regulation of β-catenin messenger 
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RNA (mRNA) expression as an important mechanism to modulate Wnt signaling and 
progression of colon cancer has not been described. 
  The transforming growth factor (TGF)-β/bone morphogenetic protein 
(BMP)/Smad4 pathway is a developmentally crucial pathway that is also frequently 
mutated in colon cancer (Grady, Myeroff et al. 1999).  BMP antagonists are expressed in 
the intestinal stem cell niche; whereas, BMP and TGF-β signaling activity increases as 
cells differentiate and migrate along the intestinal gland toward the intestinal lumen (He, 
Zhang et al. 2004, Li, He et al. 2004, Kosinski, Li et al. 2007, Perreault, Auclair et al. 
2007). Studies have included the BMP antagonist Noggin as a requisite factor within 
media for in vitro culture of isolated intestinal stem cells (Sato, van Es et al. 2011).  In 
colon cancer, TGF-β receptor type II (TβRII) is mutated in >55% of cases and BMPRI/RII 
is mutated in >70% of cases (Kodach, Bleuming et al. 2008); whereas, Smad4 mutations 
occur in 20% to 30% of cases (Miyaki, Iijima et al. 1999, Reinacher-Schick, Baldus et al. 
2004). In addition, germline mutations in Smad4 and BMPR1A genes are frequently 
found in patients with juvenile polyposis syndrome, a condition that predisposes patients 
to developing intestinal adenocarcinoma (Howe, Roth et al. 1998, Howe, Sayed et al. 
2004).  Loss of Smad4 function in the presence of Apc mutation in mice markedly 
accelerates tumor progression (Takaku, Oshima et al. 1998), but the mechanism of this 
cooperative interaction has not been fully defined. 
  Both β-catenin activation and Smad4 mutations occur frequently in colon cancer, 
yet the interaction between these signaling pathways in normal intestinal crypts and in 
colon cancer biology is unclear. In the present study, we find that decreased expression 
of Smad4 in human colon cancer is associated with increased expression of β-catenin 
mRNA. When Smad4 loss is induced in mouse intestinal tumor models, we observe 
increased expression of β-catenin mRNA and protein and associated increases in the 
mRNA expression of Wnt target genes c-Myc and Axin2. In cultured colon cancer and 
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human embryonic kidney (HEK293T) cells, both inhibition of Smad4 expression and 
inhibition of BMP receptor signaling cause similar increases in β-catenin mRNA 
expression and canonical Wnt signaling. The increase in β-catenin expression in 
response to Smad4 depletion or Noggin treatment is associated with increased 
engagement of RNA polymerase II to Ctnnb1 (the β-catenin gene). Thus, in addition to 
the important role of posttranslational modification of β-catenin in canonical Wnt 
signaling in intestinal neoplasia, up-regulation of β-catenin mRNA expression plays a 
role in further amplifying the Wnt signal after inhibition of BMP signaling or loss of 
Smad4 expression. 
Methods 
 
Human Tissues 
 
  The tissues for microarray analysis were collected and annotated according to 
our established protocols approved by the institutional review boards at the Moffitt 
Cancer Center and Vanderbilt University as previously described (Smith, Deane et al. 
2010). Tissue preparation, quality control, RNA isolation, and hybridization were 
conducted on the Affymetrix U133 Plus 2.0 platform (Santa Clara, CA) as previously 
described (Smith, Deane et al. 2010). The Gene Expression Omnibus (GEO) number 
associated with the data in this chapter is GSE17538. 
Analysis of Gene Expression Profiles 
 
  Microarray data were normalized using the RMA algorithm in the Bioconductor 
package Affy  as described (Smyth 2004); for pairwise group comparisons, t test in 
the Limma package(Zhang, Feng et al. 1996) in Bioconductor was used to identify 
differentially expressed probe sets between 2 groups under comparison (eg, normal 
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adjacent specimens vs stage I cancers). Student t test or analysis of variance was used 
as indicated in the figure legends. Grade A, 3′ biased annotated probes for Smad4 
(Affymetrix Probeset ID 202526_at) and β-catenin (Affymetrix Probeset ID 223679_at) 
probes were selected to ensure full transcript expression. Correlation analysis of scatter 
plots was performed using GraphPad Prism 5.02 (La Jolla, CA). 
Cell Culture, Transfection, and Fluorescence-Activated Cell Sorting 
 
  SW480, HCT116, and HEK293-T cells from American Type Culture Collection 
(ATCC) were cultured in RPMI (SW480, HCT116) and Dulbecco's modified Eagle 
medium (HEK293T) (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf 
serum (FCS), L-glutamine, and penicillin/streptomycin (Gibco, Carlsbad, CA). Using 
Effectene Transfection Reagent (Qiagen, Valencia, CA), SW480 cells were transiently 
transfected with 0.4-0.8μg pRK5 (empty vector) or 0.4-0.8μg pRK5-DPC4 Flag (Smad4) 
(Addgene, Cambridge, MA) (Shiou, Singh et al. 2007). Fluorescence-activated cell 
sorting was performed on SW480 cells transiently co-transfected with pRK-5 Smad4 (0.8 
μg/mL) and pEGFP (1.0 μg/mL). Cells were sorted by using the FACSAria System (BD 
Biosciences, San Jose, CA) gated at 488nm 48 hours after transfection. The top 30% of 
green fluorescent protein–expressing cells were selected for RNA and protein isolation. 
  TOPFlash and FOPFlash reporter plasmids (Millipore, Billerica, MA) with or 
without siRNA were transfected and analyzed at 48 hours after transfection by using a 
BioTek II luminometer as previously described (Dhawan, Singh et al. 2005). FOPFlash 
activity did not increase with any of the reported treatments. Luciferase reagents (Dual-
Glo Luciferase Assay System catalog no. E2940; Promega, Madison, WI) were used per 
the manufacturer's instructions. Oligonucleotide-mediated (siRNA) gene targeting was 
performed as follows: HEK293T or HCT116 cells at 30% confluence were co-transfected 
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with TOPFlash or FOPFlash, Renilla (pRL-TK, 1.0 μg/mL) plasmids, and 50 nmol/L 
control (Scrambled) or Smad4-specific siGENOME SMARTpool oligonucleotides 
(Thermo Scientific, Waltham, MA) in antibiotic-free medium containing 10% FCS for 16 
hours, according to the manufacturer's instructions. Medium was changed to 10% FCS 
media supplemented with antibiotics. Cell lysates for Western blotting were prepared 48 
hours after transfection. Conditioned Wnt3a media was obtained from L Wnt-3A cells 
(ATCC no. CRL-2647). Briefly, L Wnt-3A cells were brought up in high-glucose DMEM 
supplemented with 10% FCS, L-glutamine, penicillin/streptomycin, and G418 at 400 
μg/mL. Cells were treated with a 1:1 mixture of complete media and conditioned media 
per ATCC protocol. A BMP-response element (BRE2-Luc, a kind gift from Dr. Peter Ten 
Dijke) plasmid was used to determine BMP-mediated transcriptional activity 48 hours 
after transfection. 
Immunoblots 
  Cell lysates for Western blotting were prepared 48 hours after transfection unless 
otherwise noted. Western blotting was performed as described (Nam, Lee et al. 
2010) with 10 μg of protein lysate loaded per lane. Antibodies to β-catenin (#610154; BD 
Biosciences, San Jose, CA), Id2 (sc-489; Santa Cruz Biotechnology, Santa Cruz, CA), 
Smad1 (#06-653; Upstate Cell Signaling, Lake Placid, NY), p-Smad1 (#9511; Cell 
Signaling, Beverly, MA), Smad2 (#51-1300; Zymed Laboratories, San Francisco, CA), p-
Smad2 (#3101; Cell Signaling), Smad4 (sc-7966; Santa Cruz Biotechnology), and β-
actin (#A5441; Sigma Chemical Co, St Louis, MO) were used to detect the indicated 
proteins. 
RNA Isolation, Preparation, and Analysis 
  For RNA collection, cells were seeded equally into 6-well plates and harvested in 
parallel at 70% to 80% confluence 2 days after seeding using the Qiagen RNeasy Kit 
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   (Valencia, CA). RNA quality was assessed based on A260/A280 between 1.8 
and 2.0 and presence of intact 18S and 24S ribosomal bands by gel electrophoresis. 
RNA concentration was determined by UV spectrophotometry. Complementary DNA 
synthesis was conducted using purified 300 ng RNA and Superscript III reverse 
transcriptase (Roche, Basel Switzerland) according to the manufacturer's instructions. 
PCR amplification of complementary DNA was performed by using gene-specific primers 
(Universal Probe Library; Roche). The amplification protocol consisted of incubations at 
95°C for 15 seconds, 60°C for 1 minute, and 72°C for 1 minute for 45 cycles by using 
the Light Cycler 480 (Roche). All quantitative PCR reactions were performed in 
quadruplicate and normalized to mock transfected samples for qPCR on HEK293T or 
HCT116 cells. Statistical analysis of fluorescence was performed using Light Cycler 480 
SW Version 1.5 (Roche). 
Chromatin Immunoprecipitation Assay 
  Chromatin immunoprecipitation assays were performed by using the EZ-Magna 
ChIP Kit (catalog no. 17-408; Millipore, Billerica, MA) according to the manufacturer's 
instructions. Briefly, protein A beads (CS200637; Millipore, Billerica, MA) were coated 
with 2% bovine serum albumin overnight at 4°C. HEK293T cells were fixed in fresh 1% 
PFA for 10 minutes at room temperature. After cell and nuclear lysis disruption, lysates 
were sonicated to produce cross-linked DNA fragments that range between 200 to 1000 
base pairs in size, as determined by agarose gel electrophoresis. Lysates were 
quantitated by using the bicinchoninic acid protein assay to assess chromatin content, 
and 300 μg was loaded for an overnight incubation at 4°C with RNA polymerase II 
antibody (5 μL; catalog no. ab5408; Abcam, Cambridge, MA), anti–acetyl histone 3 (5 
μL; catalog no. 06-599B; Millipore) for positive control, or immunoglobulin G (5 μL; 
catalog no. PP-64B; Millipore) for negative control (controls not shown). The 
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immunoprecipitations were then washed and DNA isolated before qPCR analysis. DNA 
was subjected to qPCR with a SYBR Green PCR Kit (Applied Biosystems, Carlsbad, 
CA) by using the following primers: β-catenin exon 2, forward GAT TTG ATG GAG TTG 
GAC ATG GCC; reverse GAA GGA GCT GTG GTA GTG GCA C. 
Mouse Models 
 
  Smad4lox/lox and K19CreERT2 mice were obtained, bred on a C57BL/6J 
background, and crossed (Bardeesy, Cheng et al. 2006, Means, Xu et al. 2008). 
APCΔ1638/+ mice were crossed with K19CreERT2Smad4lox/lox to produce inducible Smad4 
knockout mice on APC mutant background(Fodde, Edelmann et al. 1994). The 
APCΔ1638/+K19CreERT2Smad4lox/lox mice were killed upon noting cachexia, defined as 
>20% body weight loss over 1 week (n = 5 for each time point, sex, and genotype). 
Gross determinations of polyp number in fresh tissue were verified by 2 independent 
observers. Organs were harvested, formalin fixed (10 hours, ∼1 h/mm of tissue), and 
paraffin embedded. For BrdU studies, 1mL of BrdU solution (GE) was IP injected into 
mice 1hr prior to sacrifice.  All mouse procedures were approved by the Vanderbilt 
University Institutional Animal Care and Use Committee, in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Experimental Animals. 
Laser Capture Microdissection 
  Small intestinal polyps from APCΔ1638/+K19CreERT2Smad4lox/lox mice treated with 
vehicle (n = 4) or tamoxifen (n = 4) were frozen in OTC. Frozen sections (5 μm) were cut 
and dehydrated before tissue isolation by using the Veritas 704 laser capture 
microdissection device (Arcturus Engineering, Mountain View, CA). RNA was then 
isolated from both polyp tissue areas as well as normal adjacent tissue areas by using a 
Micro RNeasy RNA Isolation Kit (Qiagen, Valencia, CA). Isolated RNA with RNA 
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integrity number values >6.5 was then amplified by using the WT-Ovation Pico RNA 
Amplification System (NuGEN, San Carlos, CA) before qPCR analysis by using the 
LightCycler 480 (Roche, Basel, Switzerland) according to the manufacturer's 
instructions. Expression of target genes in Smad4-expressing and Smad-4 deficient 
polyps was normalized by using gene expression in paired normal adjacent tissue. 
 
Immunohistochemistry 
  For immunohistochemistry of mouse tissues, either a 1:50 dilution of rabbit 
monoclonal anti-Smad4 antibody (catalog no. 1676-1; Epitomics, Burlingame, CA) or a 
1:200 dilution of rabbit monoclonal anti–β-catenin antibody (catalog no. 610154; BD 
Biosciences, San Jose, CA) was applied to fresh-cut intestinal sections. Tissue slides 
were deparaffinized, antigen retrieval was performed in citrate buffer (pH 6.0) under 
pressure for 15 minutes, and endogenous peroxidase activity was blocked by incubating 
with 3% H2O2 for 10 minutes. The sections were stained with primary antibodies at 
described concentrations and developed by using DAB substrate (Vector Laboratories, 
Burlingame, CA). Photomicrographs were taken with a Zeiss Axioplan2 equipped a 
charge-coupled device color camera (Carl Zeiss Microscopy, LLC, Thornwood, NY) at 
described magnifications and data acquisition/analysis software (Carl Zeiss Microscopy, 
LLC). 
  For immunohistochemistry on the human tissue array, we used antibodies to 
Smad4 (1:50 dilution of mouse monoclonal anti-Smad4 antibody 100 μg/mL stock; 
catalog no. sc-7966; Santa Cruz Biotechnology, Santa Cruz, CA) and β-catenin (1:800 
dilution of mouse monoclonal anti–β-catenin antibody; 250 μg/mL stock; catalog no. 
610154; BD Biosciences, Sparks, MD). Antigen retrieval was performed in EDTA at 
98°C in a decloaking chamber and quenched with H2O2. Images were captured using 
the Ariol SL-50 system (Leica Microsystems, San Jose, CA) with a 20× objective on a 
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CoolSNAP-ES charge-coupled device camera (Photometrics, Tuscon, AZ). Selected 
areas at original resolution are displayed. Controls for Smad4 and β-catenin staining 
were 12 normal adjacent colon samples and 6 adenoma samples. The cancers were 
independently scored (M.K.W.) in a semi-quantitative manner, and Fisher exact test was 
used to determine differences in proportions. Immunoreactivity intensity scores were 
determined as described previously (Galgano, Hampton et al. 2006).  
 
Results 
 
Inverse Correlation of Smad4 and β-Catenin Expression Levels in Human Colorectal 
Cancer 
 
  Although loss of Smad4 expression is associated with poor clinical outcomes in 
patients with colon cancer (Alazzouzi, Alhopuro et al. 2005), its precise role in tumor 
progression has not been fully determined. To determine whether low Smad4 expression 
is associated with increased β-catenin expression in colon cancer, we analyzed Smad4 
and β-catenin mRNA expression in a microarray data set representing 250 colorectal 
cancer patient tumor samples (stage 1, n = 33; stage 2, n = 76; stage 3, n = 82; and 
stage 4, n = 59) and 10 normal adjacent colorectal tissue specimens (Table 3.1). We 
observed a significant down-regulation of Smad4 expression in both early- and late-
stage colorectal tumors when compared with normal colon mucosa (Figure 2.1A; P< 
.0001 for all stages compared with normal [n = 10]) and significant up-regulation of β-
catenin (Figure 2.1B ; P < .002 for all stages compared with normal). To examine if 
Smad4 and β-catenin mRNA expression levels are inversely correlated on a case-by-
case basis, Pearson correlation tests were performed on the microarray data set. 
Although there was no significant correlation when examining all 250 cases (Figure 2.1C 
; P < .09), a significant inverse correlation was observed when examining stage 1 and 2  
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cases (Figure 2.1D ; P< .01). These data suggest that with loss of Smad4 expression in 
colorectal cancer there is an increase in β-catenin mRNA expression levels. 
 
Smad4 Depletion in Cultured Epithelial Cells Results in Increased β-Catenin Expression 
and Activation of TOPFlash Activity 
 
  Because the prevailing paradigm for regulation of β-catenin expression is 
posttranslational, we were surprised to find that increased β-catenin mRNA is associated 
with Smad4 loss in human colorectal cancer samples. We used HCT116 colon cancer 
cells and HEK293T cells to determine whether loss of Smad4 expression results in 
increased expression of β-catenin mRNA and protein in epithelial cells. HCT116 cells 
are human colon cancer cells that are Smad4 and APC wild type (Morin, Sparks et al. 
1997, Woodford-Richens, Rowan et al. 2001) but have mutations in β-catenin(Ser45 del) 
(Morin, Sparks et al. 1997) and TβRII (Markowitz, Wang et al. 1995). HEK293T cells are 
immortalized human embryonic kidney epithelial cells that have intact Wnt and TGF-
β/BMP family signaling pathways. When compared with scrambled small interfering RNA 
(siRNA) treatment, Smad4 siRNA-treated HCT116 cells showed a modest increase in β-
catenin protein levels (Figure 2.2A), along with a 2-fold increase in β-catenin mRNA 
expression (Figure 2.2B) and a 6-fold increase in TOPFlash activity (Figure 2.2C), 
TOPFlash is a TCF reporter plasmid that measures activation of Wnt signaling 
(Molenaar, vandeWetering et al. 1996). In HEK293T cells, knockdown of Smad4 
expression also caused a modest increase in β-catenin protein expression (Figure 2.2D), 
a 4-fold increase in β-catenin mRNA levels (Figure 2.2E), and a significant increase in 
TOPFlash activity (Figure 2.2F). Both cell lines showed increased TOPFlash activity with 
Wnt3a treatment, and both cell lines displayed a slight but not significant (P < .15) 
increase in TOPFlash activity when Smad4 siRNA treatment was combined with Wnt3a 
treatment. These data show that inhibition of Smad4 expression results in increased β-
catenin mRNA along with increased activation of a Wnt/β-catenin–activated reporter  
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plasmid, providing functional evidence of nuclear β-catenin activity, in both HCT116 and 
HEK293T cell lines. The 2-fold increase in TOPFlash activity in HEK293T cells as 
compared with the 6-fold increase in HCT116 cells is likely due to more rapid turnover of 
β-catenin in the absence of the stabilizing N-terminal mutation and an intact β-catenin 
destruction complex in the HEK293T cells.  
Smad4 Restoration Suppresses β-Catenin mRNA Expression and Represses TOPFlash 
Activity in a β-Catenin–Dependent Manner 
  The converse to blocking cellular Smad4 expression is restoration of Smad4 to 
cells that lack Smad4 expression. SW480 cells have a deletion in one Smad4 allele and 
splice site variant Smad4 mutation in the other allele (Woodford-Richens, Rowan et al. 
2001). We previously reported that restoration of Smad4 into Smad4-deficient SW480 
cells suppressed expression of the β-catenin/Wnt target Claudin-1 and that Smad4 
expression also inhibited TOPFlash activity (Shiou, Singh et al. 2007). Tian et al 
subsequently reproduced our findings and provided data suggesting that constitutive 
Smad4 expression in SW480 cells reduced β-catenin mRNA levels and decreased 
nuclear β-catenin immunoreactivity (Tian, Du et al. 2009). When Smad4 is transiently 
transfected into SW480 cells (Figure 2.3A), we observed a significant (P < .02) decrease 
in β-catenin mRNA and protein levels (Figure 2.3A,B) and a dose-dependent repression 
of TOPFlash activity (Figure 2.3C). In contrast, Smad4 did not suppress TOPFlash 
activity in SW480 cells when co-transfected with β-catenin driven by a heterologous 
promoter (Figure 2.3D). Thus, these data support a model whereby restoration of the 
Smad4 signaling pathway inhibits β-catenin expression, and the decrease in β-catenin 
accounts for the decrease in TOPFlash activation. 
Restoration of Smad4 and BMP Signaling Is Associated With Suppression of Wnt 
Signaling 
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  Prior work supports an important role for BMPs 1, 2, 5, and 7 in the modulation of 
Wnt signaling and promotion of cellular differentiation in the intestinal crypt (Li, He et al. 
2004). To determine the ligand dependence of TOPFlash activity regulation in SW480 
colon cancer cells, we co-transfected Smad4 with a well-characterized BMP-specific 
Smad reporter plasmid, BRE-Luc (ten Dijke and Korchynskyi 2002) and assessed BMP-
mediated transcriptional activity associated with restoration of Smad4 expression. 
Previous studies have shown that SW480 and HCT116 cells express BMPR1A 
receptors and are responsive to BMP2 and BMP7 (Beck, Jung et al. 2006). We selected 
BMP2 for these experiments because the BMP2 gradient is increased toward the luminal 
surface of the colonic crypt (Kosinski, Li et al. 2007). BRE-Luc activity is increased with 
Smad4 restoration (Figure 2.4A, lane 5), and this activity was augmented with the 
addition of exogenous BMP2 ligand (Figure 2.4A, lane 6). Conversely, addition of 
exogenous Noggin, a pan-BMP antagonist, caused a decrease in steady-state BRE-Luc 
activity in SW480 cells, with Smad4 expression restored even in the presence of 
exogenous BMP2 ligand (Figure 2.4A, lanes 7 and 8). These data suggest that autocrine 
and paracrine BMP signaling are restored in SW480 cells upon Smad4 re-expression. 
We and others have found SW480 cells to be refractory to TGF-β treatment but remain 
BMP responsive (Reinacher-Schick, Baldus et al. 2004, Beck, Jung et al. 2006, Shiou, 
Singh et al. 2007). To determine whether both BMP- and TGF-β–activated signaling 
results in suppression of TOPFlash, we used BMP- and TGF-β–responsive HEK293T 
cells (Figure 2.4B). BMP2 treatment of HEK293T cells suppressed TOPFlash activity, 
but TGF-β treatment did not (Figure 2.4C). In HEK293T cells, we observed a modest but 
significant decrease in β-catenin mRNA levels after treatment with BMP2 and a modest  
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but significant increase in β-catenin mRNA levels after Noggin treatment (Figure 2.4D). 
Taken together, these experiments support the conclusion that Smad4 
restoration/expression enables canonical BMP signaling to decrease β-catenin 
expression and inhibits Wnt signaling. 
BMP Signaling Regulates RNA Polymerase II Activity of Ctnnb1 
 
  To determine whether Smad4 regulates transcription of the β-catenin gene, we 
assessed RNA polymerase II bound to the 2nd exon (+460 to +579) by chromatin 
immunoprecipitation in HEK293T cells. We observed a significant decrease in RNA 
polymerase II binding at exon 2 of the Ctnnb1 gene in HEK293T cells 12 hours after 
treatment with BMP2 as compared with untreated cells. Conversely, treatment with the 
BMP antagonist, Noggin, caused an increase in RNA polymerase II engagement with  
exon 2 of Ctnnb1 (Figure 2.5A). To examine if this release of transcriptional repression 
occurs through Smad4-dependent signaling, we depleted Smad4 by using siRNA. We 
observed a significant increase in RNA polymerase II pulled down at exon 2 of 
the Ctnnb1 gene upon Smad4 depletion; however, this increase was not augmented with 
combination of Smad4 depletion and Noggin treatment (Figure 2.5B). These data 
support the conclusion that transcription of Ctnnb1 is repressed by BMP signaling 
through Smad4 and that release of transcriptional repression occurs similarly when BMP 
signaling is inhibited at the receptor level by Noggin or by depletion of Smad4. 
  
Loss of Smad4 Promotes Carcinogenesis in the Presence of Mutated Tumor Suppressor 
In Vivo 
 
  To further examine the biological significance of the preceding observations, we 
used genetically defined conditional mouse models of Smad4 depletion. For these 
experiments, we crossed Smad4lox/lox (Bardeesy, Cheng et al. 2006) mice with 
K19CreERT2 mice (Means, Xu et al. 2008) to generate K19CreERT2Smad4lox/lox. These  
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mice can be induced with tamoxifen treatment to undergo recombination of 
the Smad4 gene with resultant loss of Smad4 expression, specifically in the stem cell 
compartments of small intestine, colon, pancreas, and liver. We observed that tissue-
specific, conditional loss of Smad4 in colonic epithelium results in expansion of the zone 
of proliferative cells within the colonic crypt but not in the formation of neoplastic lesions 
(Figure 2.6A-C). In response to Smad4 depletion induced by tamoxifen treatment in the 
APCΔ1638/+ background, mouse colonoscopy readily detected tumors in the colons of 
tamoxifen-treated mice by 1 month after treatment, whereas the colons of vehicle-
treated mice appeared entirely normal (data not shown). Depletion of Smad4 resulted in 
a 10-fold increase in the tumor burden in both the large and small intestine by 5 weeks 
after tamoxifen treatment of (K19CreERT2Smad4lox/lox) × (APCΔ1638/+) mice as compared 
with vehicle-treated control mice with intact Smad4 expression (Figure 2.7A, n = 4 for the 
vehicle and tamoxifen groups).  
    Immunohistochemical analysis of the polyps from tamoxifen-treated mice showed 
that all observed adenomatous lesions (n = 12) were depleted of Smad4 protein and 
exhibited abundant nuclear β-catenin staining (Figure 2.7B,C), whereas adenomas from 
vehicle-treated mice retained Smad4 (Figure 2.6D,E). Because (APCΔ1638/+) mice rarely 
develop colonic adenomas (Fodde, Edelmann et al. 1994), we performed β-catenin 
immunostaining on the small intestinal polyps from both vehicle-treated and tamoxifen-
treated (K19CreERT2Smad4lox/lox) × (APCΔ1638/+) mice. There was a significant (P < .01) 
increase in the percentage of epithelial cells that displayed nuclear localization of β-
catenin by immunohistochemistry in the tamoxifen-treated mice (Figure 2.7D and Figure 
2.8; black arrows identify cells with nuclear β-catenin immunoreactivity, and white 
arrows identify cells lacking nuclear β-catenin immunoreactivity). 
Loss of Smad4 Is Associated with Increased β-Catenin mRNA Levels and Increased 
Wnt Target Gene Expression in Murine Adenomas 
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  qPCR analysis of mRNA from microdissected small intestinal adenomas from 
vehicle-treated and tamoxifen-treated mice showed a 6-fold increase in β-catenin mRNA 
levels in adenomas depleted of Smad4 (Figure 2.7E) when compared with normal 
adjacent tissue. For adenomatous lesions in vehicle-treated mice, in which Smad4 was 
retained, there was only a 2-fold increase when compared with normal adjacent tissue 
(Figure 2.7F). This represents a significant (P < .05) increase in β-catenin mRNA levels 
when comparing lesions that have loss of Smad4 expression with those that have 
retained Smad4 expression. We also observed increased c-Myc (Figure 2.7E; P < .05) 
and Axin2 (Figure 2.7F; P < .05) mRNA expression in lesions that have loss of Smad4 
expression when compared with those that retained Smad4 expression. These data 
indicate that loss of Smad4 is associated with increased β-catenin mRNA and Wnt target 
gene expression levels in murine adenomas. 
 
Murine Model Parallels β-Catenin Expression Pattern Observed in Human Colorectal 
Cancer 
 
  To extend these observations, we examined Smad4 and β-catenin protein 
expression patterns in tumor tissue serial sections by immunohistochemistry (n = 24; 
demographics provided in Table 2.2). Immunostaining for Smad4 and β-catenin was 
scored by grading intensity as follows: 0 = negative, 1 = weak, 2 = moderate, 3 = strong. 
Among these samples, 19 patients (∼79%) retained Smad4 expression (immunostaining 
score = 1–3), whereas 5 (∼21%) exhibited complete tumor cell loss of Smad4 
expression (immunostaining score = 0). Among those samples exhibiting complete 
tumor cell Smad4 loss (immunostaining score = 0), 4 (80%) had higher than median β-
catenin immunohistochemical staining (immunostaining score >2) when compared with 
the other tumor samples. For those tumor samples retaining Smad4 expression, only 5 
samples (∼25%) had higher than median β-catenin immunostaining (Table 3.3). Figure 
2.9 A shows a representative colon tumor section with predominant Smad4 nuclear  
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staining within the glandular carcinoma cells (black arrows). The serial section (Figure 
2.9B) is stained for β-catenin and shows that cells with predominant nuclear staining of 
Smad4 (black arrows) are associated with membrane-localized β-catenin staining. In 
contrast, a representative section from a colon tumor lacking Smad4 expression  shows 
Smad4 staining exclusively in stromal cells (Figure 2.9C) and strong nuclear and 
cytoplasmic β-catenin staining in the serial section (Figure 2.9D). Similarly, in the tumor 
retaining Smad4 expression, cells lacking nuclear Smad4 staining (Figure 2.9A, white 
arrows) correspond with strong nuclear and cytoplasmic β-catenin staining (Figure 
2.9B, white arrows). 
Discussion 
  The prevailing paradigm for regulation of β-catenin levels and Wnt signaling 
activity has been through the ubiquitin-proteasome posttranslational regulation of β-
catenin protein stability. In this chapter, we provide experimental evidence for 
BMP/Smad4-mediated repression of β-catenin mRNA expression as an alternative 
mechanism for modulating the Wnt signal. We have shown that loss of Smad4 
expression results in increased β-catenin mRNA expression and amplification of Wnt 
signaling both in vitro and in vivo. Although other studies have provided evidence for 
regulatory cross talk between TGF-β family and Wnt signaling pathways, the 
mechanisms by which this occurs have not been fully determined (Shiou, Singh et al. 
2007, Tian, Biehs et al. 2011). A recent example of this cross talk implicates up-
regulation of a novel Wnt target gene, BAMBI, in the inhibition of TGF-β signaling and 
poor prognosis in patients with colorectal cancer (Fritzmann, Morkel et al. 
2009). Increased BAMBI expression through Wnt signaling is consistent with the concept 
of a positive feedback loop in the context of colorectal cancer that would suppress TGF-
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β pathway signaling to further amplify Wnt pathway signaling and augment tumor 
progression. 
  In our human colon cancer studies, we observe complete loss of Smad4 
expression in ∼25% of samples, in agreement with others (Miyaki, Iijima et al. 1999, 
Reinacher-Schick, Baldus et al. 2004). Our data extend the prior observations to suggest 
that reduced Smad4 expression correlates with increased expression of both β-catenin 
mRNA and protein in colorectal cancers. Several prior studies have reported that 
decreased Smad4 immunoreactivity in colorectal cancer is associated with worse 
prognosis (Alazzouzi, Alhopuro et al. 2005, Isaksson-Mettavainio, Palmqvist et al. 2006, 
Tanaka, Watanabe et al. 2008). In fact, based on semi-quantitative 
immunohistochemistry scoring, patients with stage III colorectal cancer whose tumors 
exhibited low Smad4 levels had a median overall survival of only 1.7 years, whereas 
patients with high Smad4 tumor levels had a >9-year median survival (Alazzouzi, 
Alhopuro et al. 2005). Our observations that loss of Smad4 has a profound effect on the 
multiplicity and progression of intestinal adenomas in genetically modified mice raises 
the question of whether disruption of TGF-β/BMP signaling has a role in the progression 
of early human intestinal polyps. Mouse models of juvenile polyposis with BMPR1A-
deficient expression (He, Zhang et al. 2004) or Noggin overexpression (Haramis, 
Begthel et al. 2004) exhibit increased and nuclear localized β-catenin and amplified Wnt 
signaling in the intestinal polyps. The Vogelstein model places loss of heterozygosity at 
18q and loss of Smad4 in the late adenoma phase of tumor progression (Kinzler and 
Vogelstein 1996). Although loss of Smad4 expression has not been demonstrated in 
early intestinal adenomas associated with Apc mutation, Hardwick et al (Hardwick, Van 
den Brink et al. 2004) showed decreased BMP2 expression in early adenomas, which 
could result in a similar increase in β-catenin. It is likely that loss of Smad4 in more 
advanced adenomas may further amplify Wnt signaling and drive tumor progression. 
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  Our findings support the conclusion that Smad4 exerts its effect on β-catenin 
expression at the level of β-catenin mRNA, with important downstream consequences in 
Wnt signaling. However, this effect of BMP/Smad4 signaling on β-catenin mRNA 
expression is not mutually exclusive with the well-described mechanism of 
posttranslational regulation of β-catenin by APC, Axin2, and GSK3β. For example, He et 
al implicated BMP-mediated inhibition of Wnt activity through activation of PTEN, with 
inhibition of PI3 kinase and Akt activity. Blockade of BMP signaling resulted in 
inactivation of PTEN, activation of Akt with resultant inactivation of GSK3β, and 
accumulation of β-catenin (He, Zhang et al. 2004). Kosinski et al (Kosinski, Li et al. 
2007) reported that the BMP inhibitor Gremlin1 activates Wnt/β-catenin signaling in 
normal intestinal epithelial cells (IEC-18). Although intriguing, the non-canonical 
pathways implicated by He et al (He, Zhang et al. 2004) and Kosinski et al (Kosinski, Li 
et al. 2007) do not explain the significant increases in β-catenin mRNA and protein 
expression that we observe when Smad4 expression is lost. Interestingly, targeted 
disruption of Smad4 expression in the mouse hair follicle was recently shown to increase 
active cellular β-catenin and expression of the Wnt target (Yang, Wang et al. 2009) c-
Myc without increasing Akt activity or GSK-3β phosphorylation. This is consistent with 
our observations but is in contrast to the observations by He et al. (He, Zhang et al. 
2004) Our findings are also consistent with recent work showing that conditional Smad4 
loss within mouse dental mesenchymal cells results in increased β-catenin mRNA levels 
along with increased activation of canonical Wnt (Li, Huang et al. 2011). Thus, mounting 
evidence in multiple experimental systems supports the conclusion that Smad4-
dependent regulation of β-catenin mRNA expression is a biologically significant 
mechanism. 
  In the mouse, the present study supports the conclusion that induced Smad4 
loss in the intestinal epithelium stimulates the progression of intestinal neoplasia. Our 
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mouse tumorigenesis results are consistent with the 2-hit hypothesis for carcinogenesis 
as previously described by Knudson (Knudson 1971). Evidence put forth by Takaku et al 
(Takaku, Oshima et al. 1998) showed that combined mutations 
in Apc and Smad4 accelerated tumor progression in comparison to mutation 
in Apc alone. Notably, despite mosaic recombination and loss of Smad4 within only 20% 
to 30% of the intestinal glands in our studies, we observed loss of Smad4 expression in 
100% of colonic and small intestinal adenomas examined in tamoxifen-treated 
APCΔ1638/+K19CreERT2Smad4lox/lox mice. In vehicle-treated isogenic mice, 100% of the 
adenomas, almost all of which are located in the small intestine, retained Smad4 
expression. Importantly, we also observed a significant increase in expression of β-
catenin mRNA, nuclear localization of β-catenin protein, and increased expression of 
Wnt target genes Axin2 and c-Myc (Costantini, Jho et al. 2002) in Smad4-depleted 
lesions. Superinduction of c-Myc expression is particularly noteworthy in that expression 
can be transcriptionally activated by β-catenin/TCF but transcriptionally repressed by 
TGF-β/Smad signaling (Kinzler, He et al. 1998, Hoffmann and Lim 2006).   
  Our experimental results show that inhibition of BMP signaling or loss of Smad4 
can similarly augment β-catenin levels through a transcriptional mechanism, thereby 
increasing Wnt signaling. Consensus binding elements for nuclear factor κB, EGR1, 
SP1, and AP1 in the proximal β-catenin promoter have been reported (Nollet, Berx et al. 
1996), and we have noted 12 potential consensus Smad binding elements at positions 
within the 3500 bases 5-prime of the transcriptional start site of the Ctnnb1 gene. It will 
be of interest to determine whether Smad4 interacts with the β-catenin promoter to 
modulate its transcription. 
  In conclusion, we have shown that the impact of increased β-catenin mRNA 
associated with Smad4 loss is biologically significant, especially in the setting 
of Apc mutation, where the augmented Wnt signaling is associated with increased 
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Wnt/β-catenin target gene expression and an increased tumor burden. These findings 
provide potential insight into the important relationship between Smad4 loss in colon 
cancer and poor patient prognosis and late-stage disease (Alazzouzi, Alhopuro et al. 
2005, Isaksson-Mettavainio, Palmqvist et al. 2006).  Further investigation into the precise 
mechanisms underlying our observations may provide new avenues to identify 
therapeutic targets. 
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CHAPTER III  
 
LOSS OF SMAD4 IN INTESTINAL EPITHELIUM RESULTS IN DISRUPTED 
INTESTINAL HOMEOSTASIS AND IS ASSOCIATED WITH ACTIVATION OF ERK 
SIGNALING 
 
Abstract 
 
  Inactivation of the TGF-β/BMP/Smad4 pathway occurs in 50-75% of all colorectal 
cancer cases, and Smad4, the central mediator of TGF-β family of signaling, down-
regulation occurs in >50% of stage III patients.  Despite evidence supporting TGF-β and 
BMP signaling as inhibitors of intestinal epithelial cell proliferation, more remains to be 
elucidated concerning Smad4 signaling within normal intestinal homeostasis. We utilized 
two mouse models with an inducible, intestine-specific recombination of Smad4 in the 
adult animal - K19CreERT2Smad4lox/lox and Lrig1CreERT2Smad4lox/lox - to induce 
recombination at the Smad4 locus in the intestinal stem cell compartment upon 
tamoxifen treatment. Intestines from sacrificed mice were harvested for enteroid 
isolation, Ussing chamber studies, RNA-seq analysis and preservation by formalin 
fixation and paraffin embedding (FFPE). We confirmed the Smad4 status via 
immunohistochemistry and qPCR and stained FFPE sections for different cell 
populations within the crypt. To determine the role for Smad4 in intestinal response to 
injury, we also treated control and tamoxifen treated animals with dextran sodium sulfate 
(DSS). Smad4 null crypts exhibited an expansion of the Ki67 positive cells in the 
proliferative zone and fewer Carbonic anhydrase II staining cells indicating fewer mature 
enterocytes. We found that loss of Smad4 in the intestinal crypt is associated with 
increased intestinal permeability as measured by low molecular weight FITC Dextran 
using the Ussing chamber. Guided by our RNA-Seq analysis, we observe increased 
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levels of pErk in Smad4 deplete tissue. We also observed that mice with depletion of 
Smad4 developed advanced mucinous adenocarcinoma after recovery from an 
inflammatory stimulus induced by DSS. These results suggest that Smad4 loss disrupts 
intestinal homeostasis by enabling persistently high levels of Erk signaling to interfere 
with cell maturation and is associated with loss of Cdx2 expression.  
 
Introduction 
 
  Proper regulation of Wnt and BMP pathways is essential for intestinal epithelium 
homeostasis and occurs in opposite gradients along intestinal crypts (He, Zhang et al. 
2004). BMP signaling is thought to inhibit Wnt signaling, driving differentiation toward the 
luminal aspect of the crypt (Brabletz, Schmalhofer et al. 2009). BMP antagonists are 
expressed toward the base of the crypt, and transgenic mice expressing Noggin, a BMP 
antagonist, develop crypts perpendicular to the normal crypt-villous axis (Haramis, 
Begthel et al. 2004). Conditional knockout of BMPR1A in mice resulted in the 
development of intestinal polyps, inhibition of BMP signaling, PTEN activation, and 
increased levels of pAKT in association with increased β-catenin levels. In Chapter II, we 
reported that β-catenin mRNA expression is inhibited by BMP-mediated Smad4 
signaling, and loss of Smad4 signaling results in biologically significant amplification of 
the Wnt/β-catenin signal in the presence of an APC mutation.  Further, we reported in 
Chapter II that Smad4 loss in a tumor-prone murine model resulted in increased tumor 
burden and increased levels of β-catenin mRNA with associated increases in canonical 
Wnt signaling targets (Freeman, Smith et al. 2012).  
  Loss of function mutations and deletions of Smad4, a transcription factor which is 
the central mediator of TGFβ superfamily signaling (including BMP signaling), occur in 
20-30% of colorectal cancer cases and is thought to arise late in the pathogenesis of this 
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disease (Rowan, Halford et al. 2005, Lassmann, Weis et al. 2007). Loss of Smad4 has 
been associated with decreased levels of E-cadherin, liver metastasis and poor 
prognosis in Dukes C colorectal cancer patients (Miyaki, Iijima et al. 1999, Reinacher-
Schick, Baldus et al. 2004, Alazzouzi, Alhopuro et al. 2005). In the context of normal 
intestinal development, the precise mechanism of how Smad4/ TGFβ superfamily 
signaling regulates normal intestinal homeostasis is incompletely understood. Previous 
reports have examined gene expression along the crypt axis and suggest that Smad4 
activity correlates with differentiation but its function has not been examined in vivo 
(Kosinski, Li et al. 2007).  In this chapter, we observe that Smad4 loss in the context of 
normal, non-transformed intestinal epithelium results in loss of epithelial homeostasis. 
Though we observe an increase in β-catenin mRNA levels, this is not associated with 
activation of the canonical Wnt pathway but with activation of Erk signaling. Following 
colonic mucosal injury, we note that Smad4 deficient mice develop mucinous 
adenocarcinomas without the need for germline mutation of Apc or addition of a 
mutagen such as AOM. We postulate that dysregulation of Erk signaling may lead to the 
development of intestinal carcinoma and may provide a therapeutic target in patients 
which have mutations in the TGF-β/BMP/Smad signaling pathway. 
Methods 
Mouse Models 
Smad4lox/lox, K19CreERT2 and Lrig1CreERT2 (Bardeesy, Cheng et al. 2006, Means, Xu et al. 
2008, Powell, Wang et al. 2012) were obtained, bred on a C57BL/6J background, and 
crossed. These K19CreERT2Smad4lox/lox that were then treated (via intra-peritoneal [IP] 
injection) with vehicle (corn oil) or tamoxifen (0.5-1mg/20g mouse). Organs were 
harvested, formalin fixed (10hrs, approximately ~1hr/mm of tissue) and paraffin 
embedded. For antibiotic treatments, mice were treated with a cocktail 1.0g/L Ampicillin, 
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1.0g/L Enroflaxacin, 1.0g/L Metronidazole, 1.0g/L Neomycin, 0.1g/L Vancomycin, and 
30g/L Sucrose for two weeks prior to sacrifice. All mouse procedures were approved by 
the Vanderbilt University Division of Animal Care, in accordance with the NIH guidelines 
for the Care and Use of Experimental Animals.  
Intestinal Permeability 
Ussing Chamber Analysis 
To evaluate the relationship between Smad4 loss and intestinal permeability Ussing 
chamber transmucosal impedance analysis and low molecular weight FITC-Dextran (3-
5kDa) permeability assessment were performed as previously described (Clarke 2009). 
Briefly, the distal centimeter of colon was harvested and mounted on chamber units. 
Tissues were maintained in a water bath (42oC) (NESLAB EX7, Thermo Fisher 
Scientific, Newington, NH)) and monitored by multichannel voltage/current clamp VCC 
MC8 (Physiologic Instrument of Medica Research, San Diego, CA). FITC-dextran 
(80mg/mL) was added to the luminal aspect of the tissue mount and 200uL samples 
were taken from the serosal aspect every ten minutes making sure to replace volume of 
samples to ensure no pressure gradient formed. Samples were read at 480nm and 
520nm on a BioTek (Winooski, Vermont) fluorometer. 
In vivo Studies 
Mice were anaesthetized using isoflurane until non-responsive to foot pad stimulation. 
FITC-dextran solution (100μL, 80mg/mL) was delivered via enema, and mice were 
inverted for 30 min. During the procedure blood was harvested at 0 min and 30 min time 
points via cardiac puncture. Samples were read at 480nm and 520nm on a BioTek 
(Winooski, Vermont) fluorometer. 
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Enteroid Culture 
Enteroids were derived from the K19CreERT2 Smad4lox/lox by using an adapted method as 
described in Fuller et al, 2013 (Fuller, Faulk et al. 2013). Briefly, duodenum and proximal 
jejunum from approximately two month old mice were harvested and incubated in an 
1mM EDTA prior to spin down and plating in Matrigel (BD Bioscience) supplemented 
with EGF (50ng/mL), Noggin 100ng/mL, R-spondin (250ng/mL) and Wnt3a (10ng/mL).  
Each well was overlaid with DMEM/F12 (GIBCO, Carlsbad, CA) supplemented with 
HEPES 10mM), N2 (1:100), B27 (1:50), L-glutamine (1:100) and PenStrep (1:100). In 
vitro recombination was accomplished by adding 1mg/mL 4-hydroxytamoxifen (Sigma, 
St. Louis) to culture media and selecting enteroids which were null for Smad4 
expression.  
Immunostaining 
For Immunohistochemistry (IHC) of mouse tissues and to avoid mouse on mouse non-
specific staining, a 1:200 dilution of rabbit monoclonal anti-Smad4 antibody  (Epitomics, 
Burlingame, CA), a 1:2000 dilution of rabbit polyclonal anti-Ki67 antibody (Abcam, 
ab15580, Cambridge, MA) or a 1: 2000 dilution of rabbit monoclonal anti-Cdx2 antibody 
(Abcam, ab76541, Cambridge, MA) were used to stain sections from resected intestinal 
tissue. Tissue slides were deparaffinized and endogenous peroxidase activity was 
blocked by incubating with 3% H2O2 for ten minutes. The sections were stained with 
primary antibodies at described concentrations and developed using DAB substrate 
(Vector, Burlingame, CA). Photomicrographs were taken with a Zeiss Axioplan2 
equipped a CCD color camera (Zeiss AxioCam HR) and data acquisition/analysis 
software (Axiovision). 
In Situ Hybridization 
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In situ hybridization for Ascl2 was performed on 8 µm paraffin sections as previously 
described (Gregorieff and Clevers 2010). Briefly, sections were rehydrated, digested in 
proteinase K (30ug/ml), post‐fixed and hybridized at 65°C for 60 hrs with anti‐sense 
Ascl2 probes diluted in hybridization solution: 5 × Saline Sodium Citrate (SSC) (pH 4.5), 
50% formamide, 2% blocking powder (Roche), 5 mM EDTA, 1μg/ml yeast tRNA, and 50 
μg/ml heparin. Sections were washed as follows: 2 × SSC/50% formamide for 3 × 20 
min at 60°C. Sections were then rinsed in MABT buffer for 5 times for 1 min each 
followed by incubation in blocking buffer (MABT plus 10% heat inactivated goat serum 
and 1% blocking powder) for 1 hour at room temperature. Next, sections were incubated 
with preabsorbed alkaline phosphatase‐conjugated anti‐digoxigenin antibody (1/1000 
dilution) (Roche) which was diluted in blocking solution overnight at 4°C. Sections were 
washed several times in MABT and incubated with NBT/BCIP (Roche) working solution 
which was diluted in NTM buffer (0.1M Tris Cl, pH9.5, 0.1M NaCl and 0.05M MgCl2) at 
room temperature in a humidified chamber until the color develops. Sections were rinsed 
twice in PBS, dehydrated and covered with coverslips with mounting medium. The 
plasmid carrying Ascl2 (Clone IMAGE:4163833) was used as a template DNA for RNA 
probe synthesis. 
DSS Treatment 
Smad4lox/lox mice and K19CreERT2Smad4lox/lox mice were treated with vehicle or tamoxifen 
as described in Mouse Models section. One week after treatment, mice were subjected 
to three rounds of DSS exposure (5 days of 2.5% DSS water followed by 7 days of 
normal water).  
RNA Isolation, Preparation, and RNA-Seq Analysis 
For RNA collection, cells were seeded equally into 6-well plates and cells were 
harvested in parallel at 70-80% confluence two days after seeding using the Qiagen 
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RNeasy® kit (Valencia, CA). RNA quality and concentration was assessed by agarose 
gel electrophoresis and by UV spectrophotometry. cDNA synthesis was conducted using 
purified 300ng RNA and Superscript III reverse transcriptase (Roche, Indianapolis, IN) 
according to the manufacturer’s instructions.  Quantitative PCR amplification of cDNA 
was carried out using gene-specific primers (Universal Probe Library, Roche, 
Indianapolis, IN). The amplification protocol consisted of incubations at 95°C for 15s, 
60°C for 1 min, and 72°C for 1 min for 45 cycles using the Light Cycler 480 (Roche, 
Indianapolis, IN) with continuous monitoring of fluorescence to determine Cp values. All 
quantitative PCR reactions were done in triplicate. Statistical analysis of fluorescence 
was performed using Light Cycler 480 SW Version 1.5 (Roche, Indianapolis, IN). mRNA 
capture, cDNA conversion, sizing, and library construction were performed using kits 
from the Illumina Company and by following the manufacture's recommended 
procedures. For RNA-Seq application, individual libraries were constructed for 3 - 
Smad4 wild-type enteroids, 3 - Smad4 knockout enteroids, 4 - Smad4 wild-type colonic 
epithelial fractions, and 4 - Smad4 knockout colonic epithelial fractions. Each library was 
loaded into a single lane of the Illumina Genome Analyzer II flow cell. We performed 
paired-end sequencing; while for pooled sample, we performed single-end sequencing. 
Image analysis and base-calling were performed by the Genome Analyzer Pipeline 
version 2.0 with default parameters. Library construction and RNA sequencing was 
performed in the VANTAGE Core in Vanderbilt University. After obtaining the short 
reads, we performed a series of quality checks, including quality score evaluation using 
program HTSeq and marking duplicate reads by using software SAMTools. All reads 
were independently aligned to a single reference file consisting of all human transcripts 
and the human genome in the UCSC genome assembly hg18 (NCBI build 36.1) by using 
TopHat (Version 1.0.10).  
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Immunoblots 
 Cell lysates for Western blotting were prepared 48 hours after transfection unless 
otherwise noted. Western blotting was performed as described (Nam, Lee et al. 
2010) with 10 μg of protein lysate loaded per lane. Antibodies to pERK (4376-S; Cell 
Signal, Danvers, MA), Smad4 (sc-7966; Santa Cruz Biotechnology, Dallas, TX), and β-
actin (#A5441; Sigma Chemical Co, St Louis, MO) were used to detect proteins. 
 
Results 
Smad4 Loss Leads to Altered Colonic Cell Populations 
  In order to understand the function of Smad4 in the context of normal intestinal 
homeostasis, we generated an inducible, tissue specific knockout of Smad4 (Freeman, 
Smith et al. 2012).  As we have previously reported (Freeman, Smith et al. 2012), we 
used a tamoxifen-activated Cre recombinase (CreERT2) targeted to the intestinal 
epithelium to achieve deletion of Smad4 expression in intestinal epithelial crypts of 
Smad4lox/lox mice.  After tamoxifen treatment, we observed a chimeric depletion of 
Smad4 in our K19CreERT2 mouse model with approximately 20% of colonic crypts 
showing loss of Smad4 expression one month post-tamoxifen treatment.  We also 
crossed the Lrig1CreERT2 mouse to a Smad4lox/lox background to generate mice with a 
greater percentage of intestinal crypts exhibiting knockout of Smad4 (Powell, Wang et al. 
2012).  By one month after Cre activation by tamoxifen treatment, we noted that 
approximately 80% of colonic crypts in the Lrig1CreERT2 Smad4lox/lox crossbred mice no 
longer expressed Smad4, as determined by immunostaining (Figure 3.1). In Smad4-null 
crypts (denoted by black arrows, Figure 3.2B,E) we observed an increased proliferative 
zone by Ki67 immunoreactivity (Figure 3.2C,F). We observed that in the K19-driven 
CreERT2 mice that Smad4 wild-type crypts had 35.05 +/- 2.61% of cells positive for Ki67  
 66 
 
 
 
 
 
 
 
 
  
 67 
 
while Smad4 null crypts within the same section  had 54.04 +/- 3.96% (p= 0.0286, Figure 
3.2A). In our Lrig1-driven Cre model, Smad4 wild-type crypts had 39.62+/- 2.16% of Ki67 
positive cells while Smad4 null crypts had 47.68+/- 1.7% (p= 0.0121, Figure 3.2D). 
 We assessed whether this extension in the proliferative zone resulted in the 
presence of fewer mature epithelial cells within the colonic crypt. We quantified 
enterocytes (Carbonic Anhydrase II positive cells per crypt) and goblet cells (Muc2 
positive cells per crypt) in both the K19CreERT2Smad4lox/lox and the 
Lrig1CreERT2Smad4lox/lox models.  We also quantified enteroendocrine (Chromogranin A 
positive) cell populations using high powered fields in the Lrig1CreERT2Smad4lox/lox model 
that had sufficient frequency of Smad4-null crypts, due to the low number of 
enteroendocrine cells observed in individual crypts. In Smad4-null crypts (Figure 3.3 
A,C) we observed a decreased number of mature enterocytes as determined by 
Carbonic Anhydrase II (Car II) immunostaining (Figure 3.3B,D). In the K19-driven 
CreERT2 mice, Smad4 wild-type crypts had 66.89 +/- 2.45% of cells positive for Car II 
while Smad4 null crypts had 52.11 +/- 3.15% (p= 0.0303, Figure 3.6A). In the Lrig1-
driven CreERT2 mice, Smad4 wild-type crypts had 61.40 +/- 1.42% of cells positive for Car 
II while Smad4 null crypts had 43.49 +/- 1.31% (p < 0.0001, Figure 3.6B). With Muc2 
staining, we noted that Smad4-depleted crypts, denoted by black arrows, had a 
decreased number of goblet cells (Figure 3.4). We observed in the K19-driven CreERT2 
mice that Smad4 wild-type crypts had 12.44 +/- 2.47% of cells positive for Muc2 while 
Smad4 null crypts had 5.59 +/- 0.87% (p= 0.0313, Figure 3.6C). In the Lrig1CreERT2 
mice, we noted that the goblet cell population percentage varied depending on region of 
the colon in which the Smad4 depleted crypts were found. The proximal colon has more 
goblet cells than the distal colon, so we separately analyzed the proximal and distal 
colonic regions (in the K19CreERT2 mice, most of the Smad4 depleted crypts were located 
in the distal colon). In proximal glands of the Lrig1-driven CreERT2 mice, Smad4 wild-type  
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crypts had 18.78 +/- 0.78% of cells positive for Muc2 while Smad4 null crypts had 14.36 
+/- 1.32% (p = 0.0118, Figure 3.6E). In distal glands of the Lrig1-driven CreERT2 mice, 
Smad4 wild-type crypts had 11.71 +/- 2.00 % of cells positive for Muc2 while the Smad4 
knockout crypts had 5.11 +/- 0.92% (p = 0.0571, Figure 3.6D). Using the Lrig1CreERT2 
mice for determining enteroendocrine population, we identified fewer enteroendocrine 
cells in Smad4 null areas with 6.625 +/- 0.78 Chromagranin A positive cell cells per high 
powered field compared to 11.00 +/- 1.60 Chromagranin A positive cell per high power 
field (Figure 3.5) for Smad4-expressing fields (p=0.0343, Figure 3.6F). These findings 
show that Smad4 null glands have an increased proliferative zone and have fewer 
mature differentiated cells than Smad4 wild-type glands, thus, suggesting that Smad4 
signaling regulates the decision between proliferation and differentiation. 
Smad4 Loss Results in Increased Intestinal Epithelial Permeability 
  Reduced intestinal epithelial cell maturation has been thought to lead to altered 
barrier function (Madara and Marcial 1984, Madara 1989).  We therefore conducted 
studies to assess intestinal barrier function using low molecular weight FITC-dextran (3-
5kDa), to test if loss of Smad4 increased intestinal permeability in tamoxifen treated 
K19CreERT2Smad4lox/lox mice as compared to their control treated littermates with normal 
Smad4 expression. These experiments were conducted ex vivo with an Ussing 
chamber, in which FITC dextran was applied to the luminal aspect of distal colonic 
tissue, and samples were retrieved from the serosal aspect over time.  In addition, we 
monitored transepithelial resistance to current in the same experimental system.  We 
observed marked differences in the short circuit reading with greater resistance to 
electrical current in the colon from Smad4 wild-type (WT) mice as compared with 
Smad4-depleted colonic tissue (KO) (Figure 3.7A).  In addition, we observed that over 
time, more FITC dextran permeated the colons with Smad4-null glands as compared 
with Smad4 WT colons (Figure 3.7B). We then performed in vivo FITC dextran  
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permeability assays to confirm that our observations from the Ussing chamber 
experiments were not the result of sample preparation artifact. We observed a similar 
increase in FITC dextran in peripheral blood over a 30 minute period following FITC 
dextran delivery via enema (Figure 3.7C). 
 We then questioned whether the observed changes in proliferation could be 
explained due to increased injury due to microbiota being able to infiltrate the immature 
epithelial barrier (Buchon, Broderick et al. 2009, Liu, Lu et al. 2010). We treated vehicle 
and tamoxifen treated K19CreERT2Smad4lox/lox mice with antibiotics for two weeks prior to 
sacrifice (one week post vehicle or tamoxifen treatment). To confirm the efficacy of our 
antibiotics treatment we performed qPCR analysis for bacterial 16s DNA and found that 
upon treatment with antibiotics that there was marked reduction in 16s burden whether 
normalized to Selp1 or to the amount of DNA loaded (Figure 3.8A, B) (Fu, Wei et al. 
2011). We observed a similar extension of the proliferative zone in Smad4 null glands of 
antibiotic treated mice as in our sucrose-treated control mice supporting the hypothesis 
that the microbiota does not influence the proliferation phenotype (Figure 3.8C-E). 
Smad4 Loss Is Not Associated with Up-regulation of Canonical Wnt Targets 
  Since we observed a decrease in both absorptive and secretory lineages and 
reported that Smad4 depletion results in increased levels of β-catenin mRNA and 
increased canonical Wnt signaling in tumor cells (Chapter II), we asked if the extension 
of the proliferative zone was associated with increased canonical Wnt pathway signaling. 
Ascl2 is a Wnt target gene that is transcriptionally activated by canonical Wnt signaling 
via β-catenin/TCF dependent activation (Jubb, Chalasani et al. 2006). We performed 
Ascl2 in situ hybridization, to assess alterations within the Wnt signaling pathway. 
Surprisingly, we found that in crypts in which Smad4 was no longer expressed that there 
was also reduced Ascl2 mRNA levels (Figure 3.9).  
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  For more quantitative analysis, we isolated and cultured small intestinal enteroids 
from the K19CreERT2Smad4lox/lox mice and induced recombination with hydroxy-tamoxifen 
in vitro. Treatment with hydroxy-tamoxifen induced Smad4 loss within the enteroids, as 
demonstrated at both the mRNA and protein levels (Figure 3.10A,B). We then analyzed 
the mRNA for differential expression of β-catenin and Wnt targets. Despite the increase 
in β-catenin mRNA, we were not able to detect increases β-catenin protein level (Figure 
3.10B) or in mRNA for two canonical Wnt signaling targets (Axin2, c-Myc) (Figure 3.10 
C-E). 
Generation of Intestinal Smad4 Loss Gene Signature 
  Observing that our enteroid model did not implicate activation of the Wnt pathway 
with Smad4 loss, we conducted a global assessment of mRNA expression using RNA-
Seq analysis to find out how Smad4 loss alters proliferation/differentiation independently 
of β-catenin. To this end, we utilized both the enteroids from our K19CreERT2Smad4lox/lox 
mouse model and enriched isolated colonic epithelium cell fractions from the 
Lrig1CreERT2Smad4lox/lox mice to generate an intestinal Smad4-depletion gene signature. 
RNA was isolated from Smad4 WT and KO enteroids for gene expression comparison. 
We treated Lrig1CreERT2Smad4lox/lox with vehicle for control or induced recombination with 
tamoxifen treatment and waited two weeks prior to sacrificing the animals. Whole colons 
were harvested and epithelium was fractionated using an EDTA wash and mRNA 
prepared from the epithelial fraction. We first verified Smad4 depletion within the colonic 
epithelium (Figure 3.11A) and analyzed for differential expression for Wnt targets (Axin2, 
and Ascl2). We again observed increased expression in β-catenin at the mRNA level but 
no increase in downstream Wnt targets (Figure 3.11B-D). 
  We examined genes that exhibited Smad4-associated differential expression in 
the Smad4 knockout enteroids and colonic epithelium fractions from Smad4-depleted  
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mice with adjusted p-value of less than 0.01 and identified 1550 genes altered in 
enteroids and 143 genes in colonic epithelium. We found 58 common genes between 
these two lists and filtered them to find genes that changed in the same direction both in 
the enteroid and colonic epithelium fraction yielding a 44 gene Smad4 associated 
signature. Ingenuity Pathway™ analysis (IPA) of the 44 gene signature (Figure 3.12, 
Table 2.1) revealed that the top clinical disorder associated with the signature was 
gastrointestinal disease (data not shown). We then performed network analysis with the 
up-regulated and down-regulated gene sets from the 44 gene signature. The down-
regulated gene set implicated loss of TGF-β and BMP signaling with Smad4, their 
central mediator, thereby validating our model. The up-regulated genes showed Erk 1/2 
as a central node implicating activation of this signaling cascade in Smad4 null tissues. 
Erk Signaling is Activated in Smad4 Null Tissues  
  Based on the gene signature results, we then assessed phospho-Erk 1/2 
(pErk1/2) levels in the enteroid culture system and found that in Smad4 depleted 
enteroids pErk1/2 levels were increased (Figure 3.13). To further assess the effect of 
Smad4 depletion on Erk1/2 activation, we examined pErk1/2 immunoreactivity in both 
K19CreERT2Smad4lox/lox and Lrig1CreERT2Smad4lox/lox mouse models to determine whether 
Erk signaling was specifically activated in Smad4 depleted colonic crypts. In both our 
K19 (Figure 3.13B,C) and Lrig1 (Figure 3.13D,E) models, we note that where Smad4 is 
depleted pErk 1/2 is detected  at higher levels than surrounding Smad4- positive crypts 
suggesting that Smad4 depletion results in activation of Erk signaling in non-transformed 
intestinal epithelium. Previous studies have linked activation of Erk signaling with down 
regulation of Cdx2, a homeobox protein implicated in proper intestinal cell differentiation 
(Krueger, Madeja et al. 2009). We note that Smad4 null crypts in both our K19CreERT2 
(Figure 3.14A,B) and Lrig1CreERT2 (Figure 3.14C,D) have lower expression of Cdx2.  
 78 
 
 
 
 79 
 
   
 80 
 
These findings could explain the decrease in differentiation we observe in Smad4 null 
crypts. Further studies focusing on the regulation of Cdx2 by Smad4 are needed to 
establish this as a mechanism by which Smad4 loss could alter intestinal homeostasis. 
 
Intestinal Injury of Smad4 Deficient Mice Results in Development of Mucinous 
Adenocarcinoma 
  In the absence of other stimuli, the K19CreERT2 mice with depletion of Smad4 do 
not spontaneously develop intestinal tumors during a 1 year observation period.  
 Since we observed a barrier defect in the Smad4-depleted mice, we reasoned that they 
might have an impaired response to mucosal injury. We used a well-characterized model 
of dextran sodium sulfate (DSS) in drinking water to observe how Smad4 loss would 
affect response to chronic colonic mucosal injury. To do this, we treated 
K19CreERT2Smad4lox/lox with either vehicle or tamoxifen then waited one week before 
beginning three rounds 2.5% DSS treatment followed by recovery periods. We followed 
these mice monitoring weight and fecal content and observed that Smad4 knockout mice 
treated with chronic DSS developed rectal protrusion at three months of age. Upon 
sacrifice and dissection at three months of age, large non-polypoid, subluminal lesions 
were noted in the distal end of the large intestine of Smad4 knockout mice (n=7) while 
their control littermates (n=11) had no discernible phenotype (data not shown). 
Microscopic analysis showed that Smad4 knockout mice had developed invasive 
mucinous adenocarcinoma (Figure 3.15B) while their littermates showed no sign of 
injury (Figure 3.15A). Further magnification reveals dysplastic, mesenchymal-like cells 
with cyst structures forming along the basement membrane (Figure 3.15C,D). Mucin 
production in these lesions was confirmed with PAS staining (Figure 3.15E). Snail, a 
mesenchymal marker often indicative of epithelial to mesenchymal transition, was up-
regulated in the cystic lesions (Figure 3.15F).  
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Discussion 
  We noted in Chapter II that Smad4 null colonic crypts of K19CreERT2Smad4lox/lox 
have increased BrdU incorporation and here have confirmed an increase in the 
proliferative zone by Ki67 staining, and we have also extended this observation to the 
Lrig1CreERT2Smad4lox/lox model. We also observed that Smad4 null colonic crypts display 
a decreased population of differentiated colonocytes. We were unable to extend these 
observations to small intestine due to Smad4 expression being detected in >90% of the 
glands by immunohistochemistry (IHC) approximately one month post-tamoxifen 
treatment (data not shown). We postulate that the loss of Smad4 in the small intestinal 
crypt may lead to a competitive disadvantage resulting in repopulation of the small 
intestine by Smad4 expressing crypts over time, possibly through crypt fission. Future 
studies comparing the number of Smad4 null crypts over time will be needed to test this 
hypothesis. However, the recombination events in the large intestine for both the 
K19CreERT2and Lrig1CreERT2 models have been maintained for greater than three 
months suggesting no competitive advantage of Smad4 expressing glands in colonic 
epithelium or that we have not observed the mice for enough time to observe the 
replacement of Smad4 null glands.  
  There are some discrepancies in numbers observed for different populations 
between our K19CreERT2 and Lrig1CreERT2 models (e.g. Car II stained 52.11 +/- 3.15% in 
K19-driven CreERT2  in Smad4 null crypts [Figure 3.6A] while Lrig1-driven CreERT2 mice, 
Smad4 null crypts had 43.49 +/- 1.31% cells stain positive for CarII). This may be 
attributed to the CreERT2 coding sequence being knocked-in to endogenous alleles, 
effectively deleting one copy of Krt19 or Lrig1, respectively. These loci could have 
important roles in normal crypt development especially for the Lrig1CreERT2 model 
because the homozygous Lrig1CreERT2 mouse, with both alleles for Lrig1 replaced with 
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CreERT2, develop spontaneous duodenal polyps (Powell, Wang et al. 2012). Lrig1 
functions as pan-ErbB inhibitor; therefore, complete loss of Lrig1 expression should 
enhance EGFR signaling. As discussed in Chapter I, EGFR signaling functions in 
maintenance of the intestinal stem cell niche (Biteau and Jasper 2011), and EGFR 
pathway activation leads to progression through the cell cycle (Oda, Matsuoka et al. 
2005). However, we maintained our Lrig1CreERT2 model as a hemizygous CreERT2, and 
no phenotype was previously reported for mice with a single knock-in allele. Regardless, 
we observed similar significant differences in cell populations (enterocytes, goblet cells, 
and enteroendocrine cells) in our two different conditional knockout models with fewer 
mature cells observed in Smad4 null crypts compared to Smad4-expressing crypts. 
Because both models gave similar results, we are confident that the decreased 
differentiation observed is due to the loss of Smad4 expression rather than Krt19 or 
Lrig1 haploinsufficiency. 
  In Chapter II, we observed that when Smad4 was knocked down in HCT116 
cells, which possess an activating mutation of β-catenin, that β-catenin levels increased 
at both mRNA and protein levels, resulting in activation of canonical Wnt signaling 
(activation of TOP-Flash reporter). However, in the K19CreERT2 enteroids and 
Lrig1CreERT2 colonic models presented here, we observed that despite increases in 
mRNA expression of β-catenin that there is not an up-regulation of conventional Wnt 
signaling targets (Axin2, Ascl2, c-Myc, etc.). This could be attributed to the presence of 
an intact β-catenin degradation complex and wild-type β-catenin enabling cells to 
maintain a steady level of β-catenin protein despite an increased mRNA expression 
level. In Figure 3.9, we noted that Smad4 null crypts had less expression of Ascl2 by in 
situ hybridization. This suggests that Smad4 loss is altering the intestinal stem cell niche. 
Within our enteroid culture we noted that there is increased budding in Smad4-null 
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enteroids as compared to Smad4-expressing enteroids (data not shown) suggesting that 
there may be increased stem-like cells within the Smad4 null tissues. Understanding the 
role of Smad4 in maintenance of the stem cell niche within non-transformed epithelium 
could be investigated using our mouse models.  
  Within the Smad4 null mouse colonic crypts, we noted that there is decreased 
expression of Cdx2. Cdx2 is a homeobox protein that has been implicated in intestinal 
cell differentiation and identity (Krueger, Madeja et al. 2009, Grainger, Savory et al. 
2010). Cdx2 has been shown to be down-regulated in colon cancer and inversely 
correlated with lymph node metastasis (Bakaris, Cetinkaya et al. 2008).Knocking out 
Cdx2 expression in Apc mutant mice resulted in increased intestinal tumor burden (Aoki, 
Kakizaki et al. 2011).  In the Caco-2 cell line, a colon cancer cell line that undergoes 
differentiation, Cdx2 expression was shown to decrease Wnt pathway activation, 
possibly through increased expression of APC and Axin2 (Olsen, Coskun et al. 2013), 
and stimulate an epithelial phenotype through increased expression of E-Cadherin 
(Natoli, Christensen et al. 2013). Within intestinal epithelium, ablation of Cdx2 resulted in 
increased proliferation and inability of cells to terminally differentiate into intestinal 
epithelium (Gao, White et al. 2009). Interestingly, in colorectal cancer cases, Cdx2 is 
rarely mutated suggesting that its expression is determined by transcriptional regulation 
(Hinoi, Loda et al. 2003). Understanding the mechanisms by which Smad4 signaling 
influences Cdx2 expression in our model system is an important future direction for this 
study.  
 Previous work that reported knocking out the BMP receptor pathway of signaling 
within the intestinal tract showed some similarities and some important differences 
compared to our Smad4 knockout models. It should first be noted that Smad4 serves as 
the central universal transcriptional mediator for all canonical TGFβ pathway signaling 
while silencing subfamily receptors only inhibit that specific pathway. Our results pointed 
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to an increased proliferative zone with fewer mature colonocytes in Smad4 null crypts. In 
one prior study utilizing the Mx-1-Cre to knockout Bmpr1a, the authors showed an 
extended proliferative zone within dysplastic regions of the small intestine that have lost 
expression of Bmpr1a; however, their analysis was skewed by these regions being 
transformed (He, Zhang et al. 2004). In addition, their recombination event was driven by 
Mx-1-Cre, and Mx-1 is expressed in multiple organ systems and functions in the defense 
of viral infections (Kuhn, Schwenk et al. 1995). This limits the interpretation of results 
since multiple systems and particularly the inflammatory system, could also be targeted. 
This is worth noting due to other observations that loss of Smad4 signaling within the T-
cell compartment can also lead to intestinal tumor development (Kim, Li et al. 2006). 
Another group utilized Villin-Cre to remove intestinal expression of Bmpr1a (Auclair, 
Benoit et al. 2007) and found an extension of the proliferative zone within the small 
intestine. They also noted a decreased number of enteroendocrine cells within the small 
intestine but did not observe any changes in goblet, paneth, or enterocyte population 
number. However, their analysis of enterocytes population numbers may be misleading 
as they utilized Fatty Acid Binding Protein and Sucrase-Isomaltase, the former of which 
appears to mark most intestinal epithelial cells and the latter which, from their staining, 
does not mark all mature enterocytes. Later in their work, they performed qPCR analysis 
of duodenal and jejunal tissues and noted down-regulation of mature markers for 
enterocytes (not significant), Paneth, enteroendocrine, and goblet (significant (p<0.05 for 
all three). Given our results in which we note increased Erk activation and decreased 
expression of Cdx2 within Smad4 null colonic crypts, it would be interesting to 
investigate whether these other mouse models show a similar expression pattern as to 
further understand how loss of Smad4 signaling results in altered intestinal homeostasis.  
  From our studies, we conclude that Smad4 loss in the context of normal, non-
transformed intestinal epithelium results in loss of epithelial homeostasis. Though we 
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observed an increase in β-catenin mRNA levels, this is not associated with Wnt pathway 
activation but with activation of Erk signaling. Following colonic mucosal injury, we note 
that Smad4 deficient mice develop mucinous adenocarcinomas without the need for 
germline mutation of APC or addition of a mutagen. We postulate that dysregulation of 
Erk signaling may lead to the development of intestinal carcinoma. Understanding the 
mechanism of Erk pathway activation could prove fruitful in designing a therapy in 
tissues which have loss Smad4 signaling. 
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CHAPTER IV 
 
 
 
 CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
Brief Review 
 
 
  The epithelium of the intestinal tract is highly dynamic and strikes a careful 
balance between proliferation to maintain an intact interface and stem cell niche and 
differentiation to perform the functions such as nutrient absorption and barrier function. 
Perturbations in this balance have been implicated in carcinogenesis and can lead to 
increased proliferation and decreased differentiation as seen in colon cancer. Normally, 
Wnt signaling maintains the intestinal stem cell compartment and proliferative zone 
(Willert, Brown et al. 2003) while TGF-β family of signaling is thought to drive 
differentiation (Kosinski, Li et al. 2007) (Figure 1.4). Inappropriate Wnt pathway 
activation occurs frequently in colorectal cancer cases. Often this activation is 
associated with mutations in APC resulting in the inability to degrade β-catenin, the 
central mediator of the Wnt pathway (Laurent-Puig, Beroud et al. 1998). However, 
analysis of human tumor tissue reveals that mutation in APC or β-catenin was not 
sufficient to develop cancerous lesions (Figure 1.6) or to observe maximal levels of 
canonical Wnt signaling, suggesting that signals from the microenvironment may also 
affect Wnt signaling levels (Fodde and Brabletz 2007).   
  Among the other pathways implicated in colorectal cancer,  alterations in TGFβ 
superfamily signaling occur in some 50-75% of all colorectal cancer cases, and Smad4, 
the central mediator of TGFβ superfamily signaling, is down-regulated in  >50% of stage 
III patients (Isaksson-Mettavainio, Palmqvist et al. 2006). This loss of Smad4/TGFβ 
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signaling either early or late in tumor progression is associated with poorer prognosis 
(Alazzouzi, Alhopuro et al. 2005, Mesker, Liefers et al. 2009).The exact mechanism of 
how Smad4 signaling regulates Wnt signaling has not been reported nor has Smad4’s 
role in maintaining intestinal homeostasis. We utilized biological models to investigate 
the role of Smad4 in maintaining intestinal homeostasis and in tumor progression.   
  In Chapter II (Freeman, Smith et al. 2012):  We investigated the regulation of β-
catenin by Smad4 and described a new role of the tumor suppressor Smad4 in the 
transcriptional repression of β-catenin. In the context of transformed tissue, we observed 
an increase of canonical Wnt signaling and a dramatic increase in tumor burden when 
the Smad4 gene was deleted in an Apc mutant background. We  have extended the 
findings reported by Takaku et al (Takaku, Oshima et al. 1998) which showed that 
combined germline heterozygous mutation of Apc and Smad4 alleles accelerated tumor 
progression in comparison to mutation of Apc alone. We did so by generating an 
inducible, tissue selective knockout of Smad4 expression in the adult mouse, thereby 
producing a model which more closely recapitulates the pathogenesis of human 
colorectal cancer. Importantly, we also observed a significant increase in expression of 
β-catenin mRNA, nuclear localization of β-catenin protein, and increased expression of 
Wnt target genes Axin2 and c-Myc (Costantini, Jho et al. 2002) in Smad4-null lesions 
compared to Smad4-expressing tumors from control animals.  This finding was 
corroborated by analysis of tissue microarrays from human colorectal cases and 
observing that cases which do not retain Smad4 expression showed increased levels of 
β-catenin, supporting our murine model as a means to study human colorectal cancer. 
  Our in vitro experimental results show that inhibition of BMP signaling or loss of 
Smad4 in colon cancer lines can similarly augment β-catenin levels through a 
transcriptional mechanism, thereby increasing Wnt signaling. This finding suggests that 
Smad4 regulates β-catenin downstream of BMP signaling rather than TGFβ signaling at 
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least in the cell lines tested. Interestingly, our findings are consistent with work showing 
that conditional Smad4 loss within mouse dental mesenchymal cells results in increased 
β-catenin mRNA levels along with increased activation of canonical Wnt (Li, Huang et al. 
2011). Thus, mounting evidence in multiple experimental systems supports the 
conclusion that Smad4-dependent regulation of β-catenin mRNA expression is a 
biologically significant mechanism. 
   In Chapter III, we observed novel functions for Smad4 in intestinal homeostasis. 
We observed that loss of Smad4 is associated with an increased proliferative zone and a 
decrease in mature colonocytes within the large intestinal crypt. While loss of Smad4 in 
non-transformed intestinal epithelium results in increased expression of β-catenin mRNA 
there was no detectable increase in β-catenin protein or a functional increase in Wnt 
pathway activation. Instead, in this context, we observed an increase in Erk activation. 
Constitutive Erk activation has been associated with inhibition of differentiation in 
association with down-regulation of Cdx2, a homeobox protein implicated in intestinal 
differentiation (Lemieux, Boucher et al. 2011). We observed that Smad4 null crypts also 
have lower expression of Cdx2 which could potentially explain our observation of 
decrease in mature colonocytes. DSS treatment of mice with Smad4 null crypts resulted 
in development of invasive mucinous adenocarcinoma suggesting that persistent Erk 
signaling could predispose this model to tumorigenesis. Overall, these results provide 
insights into the role of Smad4 in maintaining normal intestinal homeostasis and how its 
loss can promote tumorigenesis. 
  The contribution of this research has been to further elucidate how Smad4 
signaling functions in normal intestinal homeostasis and that Smad4 signaling 
suppresses canonical Wnt signaling in the context of transformed tissue. This 
contribution is significant because a majority of all colorectal cancer cases have 
mutations in Smad4/TGFβ/BMP signaling (Isaksson-Mettavainio, Palmqvist et al. 2006). 
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Our work shows that loss of Smad4 in tumors could promote tumor 
maintenance/dissemination via cell autonomous effects such as proliferation. These 
results suggest that restoring Smad4 activity may make tumors less aggressive. While 
gene therapy remains non-viable for treating most human diseases, further research to 
replicate the effects of Smad4 through therapeutic treatment could prove fruitful. This 
therapeutic approach could be utilized in the >80% of colorectal cancer cases in which 
the Wnt pathway is aberrantly activated.  
Future Direction for Smad4 Repression of β-catenin Transcription 
  We observed that both Noggin treatment and Smad4 depletion result in 
increased transcription of β-catenin (Figures 2.2, 2.4, 3.10, and 3.11). Further, we noted 
that this regulation of β-catenin is lost upon expressing β-catenin under the control of a 
heterologous promoter (Figure 2.3). There are at least 12 potential Smad binding 
elements in the 3400bp 5’ to the CTNNB1 (the gene encoding β-catenin) transcriptional 
start site along with several other consensus transcription factor binding sites (Figure 
4.1A) suggesting that Smad4 may directly regulate the transcription of the CTNNB1 
gene. Using a CTNNB1 promoter reporter plasmid assay, we noted that Smad4 
depletion results in increased reporter activity (Figure 4.1B). This all supports the 
hypothesis that Smad4 has a transcriptional repression effect upon the CTNNB1 gene; 
however, much remains to be elucidated concerning the mechanism of this 
transcriptional regulation. 
  First, what region of the CTNNB1 promoter is needed for Smad4 signaling to 
repress expression?  Using the promoter reporter construct described (Nollet, Berx et al. 
1996), we can generate 700bp fragment deletions from the 5’ end to identify regions that 
are important for regulation by Smad4 following treatment with BMP and/or Noggin and 
with and without Smad4 depletion by siRNA. Based on the deletion studies, we could 
pinpoint fragments of interest in the promoter to generate a series of mutant constructs,  
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also fused to a reporter construct, and assess the activity of these reporters under 
identical treatment conditions. This will determine which specific sequence elements are 
required for the suppressive effect of Smad4 upon β-catenin promoter driven reporter 
expression.   
  Second, is the transcriptional regulation a result of direct binding of Smad4 to the  
CTNNB1 promoter?  Chromosome immunoprecipitation can be performed on prepared 
nuclear lysates using antibodies against Smad4 and PCR amplification of Smad4- 
responsive elements described above. Quantitative PCR amplification of putative Smad 
binding sites from the CTNNB1 promoter regions can be compared to binding sites of 
known BMP targets (e.g. Id2). Promoter binding will then be corroborated by 
electrophoretic mobility shift assays.  In order to further determine the co-regulators that 
may be cooperatively binding with Smad4 present, we can take a candidate approach 
with a series of co-immunoprecipitation (Co-IP) experiments to determine whether 
immunoprecipitated nuclear Smad4 is bound to Smads1/5/8, Smads2/3 or with the co-
repressors: E2F4/5, Nkx3.2, Runx2, p107, Sin3, or HDAC4 in nuclear lysates(Figure 
4A).  Once candidate co-repressors are identified, siRNA knockdown of each candidate 
co-repressor can be performed to elucidate which of the co-repressors are necessary for 
BMP-mediated transcriptional repression of the CTNNB1 gene. 
We predict that reporter activity will increase when the BMP responsive elements 
of the β-catenin promoter are mutated since Smad4 would no longer be able to bind to 
the promoter region. We have experimentally demonstrated the repressive effect of 
BMP-mediated Smad4-dependent signaling on β-catenin mRNA expression and expect 
to show that Smad4 regulates transcription at the β-catenin promoter. Our experiments 
are designed to determine whether these effects are direct or indirect. If there is no 
change in reporter activity after mutating single regions of interest, combination of 
mutation sites encompassing possible response elements will be tested. We anticipate 
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that mutation of specific gene elements will result in some change in the affinity of co-
regulators, such as HDACs to the CTNNB1 promoter; detection of these interactions 
may require chemical cross-linking to capture transient complex formation on the 
promoter (Massague, Seoane et al. 2005). In addition, tandem mass spectroscopy 
studies can increase the sensitivity and may be able to identify unanticipated, difficult to 
detect, and possibly novel, binding partners present in the repression complex.  
Finally, we have shown an increase in β-catenin mRNA expression upon Smad4 
depletion in the presence of an intact β-catenin degradation complex does not translate 
into increased β-catenin protein levels/increased Wnt pathway activation. We 
hypothesize that the APC-degradation complex maintains a constant level of β-catenin 
protein even when β-catenin mRNA is elevated and that Smad4 loss only alters Wnt 
pathway activation when the APC-degradation complex is inhibited or down-regulated. 
However, we have yet to test this experimentally. We are currently breeding 
APCΔ1638/+Lrig1CreERTSmad4lox/lox mice in an attempt to answer this question by isolating 
mRNA and protein from colonic epithelium of these mice four days post treatment with 
either vehicle or tamoxifen. With this loss/truncation of a single allele of APC, we would 
be able to determine if loss of Smad4 can increase β-catenin protein level and increase 
in Wnt targets (such as Axin2, c-Myc, and Ascl2) when there is reduction, rather than 
complete loss of the degradation complex. This may uncover a physiological as opposed 
to pathophysiological role for Smad4. Given that APCΔ1638 model depends on loss of 
heterozygosity to produce intestinal tumors, the single copy of wild-type APC may be 
enough to prevent β-catenin protein accumulation and activation of Wnt signaling. 
However, we predict that upon depletion of Smad4 that in the presence of one mutant 
copy of APC that we should see elevated levels of β-catenin protein and expression of 
Wnt targets.  
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Future Direction for Smad4 Signaling in Maintaining Normal Intestinal 
Homeostasis 
  We have presented data in Chapter III (Figure 3.9) that show that crypts which 
are null for Smad4 expression have qualitatively less Ascl2, a canonical Wnt pathway 
target gene, mRNA by in situ hybridization. On further investigation of this observation in 
the enteroid model and in isolated colonic epithelium from our Lrig1CreERT Smad4lox/lox 
we see no significant difference in Ascl2 expression (Figure 4.2 B, E). However, we did 
observe that certain markers such as Lrig1 (Figure 4.2 C) in our colonic epithelium are 
increased in its expression. This suggests that loss of Smad4 expression results in 
alterations within the intestinal stem cell niche. Within the intestinal tract, injury results in 
increased Lrig1 expressing cells within the crypt (Powell, Wang et al. 2012). This could 
suggest that we are altering the local environment to an injured state (discussed in detail 
below). We are currently generating mice for frozen sections for immunofluorescence to 
investigate if this increased expression of Lrig1 mRNA results from a greater number of 
cells expressing Lrig1 or from the same number of cells expressing higher levels of 
Lrig1.  
 We observed in Chapter III that Smad4 depletion followed by treatment with DSS 
results in development of invasive mucinous adenocarcinoma without the presence of a 
germline mutation in APC (Figure 3.15). While we have observed an increase in Erk 
pathway activation with Smad4 loss, the manner of tumorigenesis remains to be 
elucidated. To accomplish this, we are collecting mRNA from our tumor and normal 
adjacent tissue to identify what pathways are activated/have mutations in them allowing 
us to understand what is driving/sustaining the tumor. We are also harvesting large 
intestine at earlier time-points to capture what occurs early in this adenocarcinoma 
pathogenesis. Based on the mucinous nature of these lesions, we hypothesize that an 
activation of PI3K pathway may be implicated in tumor development; however, this is 
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based solely on the phenotype of the tumors (Leystra, Deming et al. 2012). 
  In Chapter III, we observed activation of Erk signaling was associated with loss of 
Smad4. Previous work has pointed to activation of Erk signaling by BMP/TGF pathway 
signaling (Kleeff, Maruyama et al. 1999, Zhang 2009). More pertinently, prior work in 
Capan-1 cells, a Smad4-mutant pancreatic adenocarcinoma, showed that treatment with 
BMP2 resulted in activation of the MAPK pathway and that re-expression of Smad4 
resulted in loss of the MAPK pathway activation by BMP2 treatment (Kleeff, Maruyama 
et al. 1999). This result suggesting that BMP treatment resulted in non-canonical 
activation of the MAPK pathway prompted us to examine whether the activation of Erk 
that we observed in our model systems could be attributed to non-canonical BMP 
signaling. To test this, we treated Smad4 null colonocytes and Smad4-depleted (via 
siRNA) HEK293T cells with BMP2 or Noggin. We observed that no change in pErk 
levels in Smad4-expressing cells (Figure 4.3 A,B). However, Noggin treatment of Smad4 
null colonocytes or Smad4-depleted HEK293T cells resulted in lower pErk levels 
suggesting that BMP signaling could be activating Erk signaling through a non-canonical 
pathway. Interestingly, we also observed that Smad4 null/depleted cells actually 
displayed lower levels of pErk as compared to Smad4 expressing cells, which is 
opposite of what we observed in our enteroid system and within colonic epithelium 
(Figure 3.13). The reasons for these paradoxical observations are not entirely clear; 
however, we postulate that these differences may be due to different response in 2D 
monolayer cell cultures and the enteroids/crypts that represent a 3D system in which 
differentiation is able to transpire. Further studies are needed to further interrogate the 
non-canonical signaling downstream of the TGF-β/BMP receptor activation. These 
experiments will include comparative treatments with Noggin or exogenous BMP to 
determine if BMP treatment can specifically cause activation of Erk in this system. It will 
also be important to extend this analysis to a cell line such as Caco-2 that has been  
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shown to differentiate in culture. 
  The focus of this project has been primarily upon how loss of Smad4 within the 
epithelial compartment affects intestinal homeostasis by measuring alterations within the 
epithelium itself; however, the intestinal tract is composed of more than simply 
epithelium. While this gross simplification enabled us to focus on specific questions in 
regards to epithelial biology, there is data to suggest that we are altering the surrounding 
mesenchyme within the tissue in a cell non-autonomous manner. We have begun 
investigating these alterations using our Lrig1CreERTSmad4lox/lox mouse model. After 
induction of recombination with tamoxifen treatment, we harvested the colon and have 
isolated the colonic epithelium using an EDTA wash and what remains is our 
mesenchymal fraction. We have submitted these samples for RNA-Seq and found that 
we have enrichment for B-cell signaling within the colonic mesenchyme of 
Lrig1CreERTSmad4lox/lox treated with tamoxifen versus those mice that have been treated 
with vehicle (data not shown). We also have generated evidence from whole tissue 
isolation that loss of Smad4 within the epithelial compartment can influence inflammatory 
aspects of intestinal tissue. We found that both T-cells (Figure 4.4A,B) and macrophages 
(Figure 4.4D-G) were surrounding Smad4 null crypts. Using the Luminex assay (Barry, 
Asim et al. 2011) and whole tissue lysate from colonic  epithelium, we observed an 
increased expression of MIP3a (Ccl20) (Figure 4.4C). We are planning to flow sort 
immune cells in our Lrig1CreERT Smad4lox/lox model to ascertain shifts which occur in 
inflammatory cells due to loss of Smad4 expression within the epithelial compartment. 
From our limited data, we would anticipate that an overall increase in the number of 
tissue T-cells and macrophages within colonic tissue; however, we are unsure whether 
these infiltrating immune cells will be immunosuppressive or pro-inflammatory. 
  Further studies were performed to ascertain whether Ccl20 expression could be 
originating from intestinal epithelium. We examined Ccl20 in the colonic epithelial 
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fraction from our Lrig1CreERT Smad4lox/lox mouse model and found that Smad4 null cells 
expressed higher levels of CCL20 (Figure 4.5C). We utilized immortalized colonocytes 
isolated from Smad4lox/lox mice and treated them with either Adeno-GFP for control or 
Adeno-Cre to induce recombination. We then clonally selected cells for loss of Smad4 
expression (Figure 4.5A).  We examined these cells for differential expression of CCL20 
and found that Smad4 null colonocytes expressed more Ccl20 mRNA than did Smad-4-
positive colonocytes (Figure 4.5B).  We then asked if this regulation could perhaps be 
regulated by BMP signaling or is mediated through secreted stromal ligands. To this 
end, Smad4 wild-type (wt) colonocytes were treated with BMP2 and/or conditioned 
media from immortalized mouse pericryptal fibroblasts (IMPF). In control (fresh) media, 
we found that with increasing exogenous BMP2 there was a slight decrease in Ccl20 
expression (Figure 4.5D). Since BMP inhibitors are expressed by stromal cells 
surrounding intestinal epithelium, we tested the hypothesis that stroma normal regulates 
Ccl20 via the BMP pathway. There was a significant increase noted in Ccl20 expression 
when Smad4 wt colonocytes were treated with conditioned media from IMPF suggesting 
that there may be cross-regulation of epithelial expression of Ccl20 through surrounding 
mesenchyme. Adding increasing amounts of exogenous BMP2 abrogated this increase 
in Ccl20 expression, suggesting that pericryptal fibroblasts regulate Ccl20 expression via 
repression of BMP signaling. This repression becomes constitutive when Smad4 is 
deleted. 
  We hypothesize that IMPFs secrete a BMP pathway antagonist (e.g. Noggin, 
Gremlin, etc.) to counteract the regulation of BMP signaling upon CCL20 expression. We 
could knock down candidate factors from IMPF and observe which factor is necessary 
for this regulation of CCL20. We ultimately plan to confirm these findings in an in vivo 
system using a BMP inhibitor to see if a similar up-regulation of CCL20 is observed. 
Since CCL20 is known to recruit Th17 cells and modulate their immune response 
 100 
 
(Comerford, Nibbs et al. 2010), we could extend these in vitro observations into a murine 
model that lacks CCR6, the receptor that is specific for binding with CCL20, to  
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determine how loss of Smad4 influences immune response with and without the 
CCL20/CCR6 axis intact. We predict that without CCR6 that a Th17 response would be 
dampened. It would be interesting to extend these studies to our tumor models and 
observe how the CCL20/CCR6 axis affects tumor incidence and burden. We would 
predict that a dampened inflammatory response that there would be fewer tumors. 
However, Th17 cells have been shown to be both pro-inflammatory and 
immunosuppressive, so it would be interesting to observe what Th17 population is 
present in the context of loss of epithelial Smad4 expression. 
Summary 
  Within the intestinal tract, a delicate balance between proliferation and 
differentiation must be maintained to ensure proper tissue function. Dysregulation of 
many pathways have been implicated in the pathogenesis of colorectal carcinoma; 
however, a large portion of CRC cases have mutation in the Wnt pathway (>80%) and a 
majority has a mutation within the BMP/TGF-β signaling pathway. Herein, we have 
generated a mouse model that recapitulates pathogenesis of colorectal cancer to gain 
insight into the role of a key transcription factor Smad4, the central mediator of TGF-β 
signaling pathway, plays in intestinal homeostasis. In the context of non-transformed 
intestinal epithelium, we observed an increase in proliferation, a decrease in mature 
colonocytes, and increased inflammation when Smad4 is lost. These findings are 
associated with an increase in Erk pathway activation and increased β-catenin mRNA 
but not increased Wnt pathway activation. In the context of transformed epithelium, we 
observed that Smad4 depletion leads to increased β-catenin mRNA and in the presence 
of APC mutation this resulted in an increase in canonical Wnt pathway activation and 
increased intestinal tumor burden. Overall, these results provide insights into the biology 
of intestinal homeostasis and into colorectal carcinoma progression. 
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APPENDIX 
XIAP Monoubiquitylates Groucho/TLE to Promote Canonical Wnt Signaling 
 
  We collaborated with Allison Hanson and the Lee Laboratory in their study 
describing the role of XIAP, mammalian homologue of Drosophila Diap1, as a ubiquitin 
ligase for Groucho(Gro)/TLE (Hanson, Wallace et al. 2012). Hanson et al. identified 
Diap1 as an activator of Wingless signaling in Drosophila S2 cells and then went on to 
test the function of the mammalian XIAP in HEK293T and SW480 cell lines via siRNA 
knockdown. They found increased activity in TOP Flash, a reporter plasmid utilized to 
detect activation of canonical Wnt signaling when XIAP was reduced. For our part in this 
project, we perform qPCR analysis on Wnt target gene Axin2 upon depletion of XIAP 
(Figure A.1A Panel ii and Figure A.1B Panel ii) in HEK293T cells and SW480 cells. 
HEK293T cells were transfected with scrambled siRNA (Con) or siRNA targeting XIAP 
(as indicated in Figure A.1A Panel i) then cells were treated with exogenous Wnt3a for 
24 hours in order to induce Wnt pathway activation. In cells that were treated with 
exogenous Wnt3a and control siRNA, we observed an increase in mRNA expression by 
qPCR (Lane 2, Figure A.1A Panel i) ; however, HEK293T cells that had XIAP depleted 
via siRNA transfection (Lanes 3-4, Figure A.1A Panel i) had Axin2 levels that were 
significantly reduced when compared to the Wnt3a stimulated cells treated with 
exogenous Wnt3a. XIAP depletion in SW480 cells showed a similar reduction in Axin2 
expression (Figure A.1B Panel i) without need of exogenous Wnt treatment since 
SW480 cells have constitutively high levels of Wnt pathway activation. Hanson et al. 
went on to elegantly show that XIAP ubiquitilates Gro/TLE and this in turns disrupts 
Gro/TLE interaction with TCF. β-catenin then can bind with TCF and drive transcriptional 
program associated with activated canonical Wnt signaling. 
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Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome 
 
 
 We collaborated with Amanda Hansen and the Zijlstra Laboratory in their work 
describing cleaved ALCAM correlating with poor colorectal cancer prognosis (Hansen, 
Freeman et al. 2013). Previous reports were contradictory as to whether overexpression 
of ALCAM or loss of ALCAM expression could function as a prognostic marker in 
colorectal cancer (Weichert, Knosel et al. 2004, Levin, Powell et al. 2010, Lugli, Iezzi et 
al. 2010, Tachezy, Zander et al. 2012). For our contribution to this work we provided 
microarray data from our 250 colorectal cancer patient dataset as well as the survival 
outcome associated with this patient dataset. We observed higher expression of ALCAM 
in colorectal cancer cases compared to normal tissue (Figure A.2A) and that higher than 
median expression of ALCAM associated with poor patient outcome (Figure A.2B). We 
also observed increased expression of ADAM17, the metalloprotease which cleaves 
ALCAM, in cancer cases (Figure A.2C); however, higher than median expression of 
ADAM17 did not significantly associate with poor patient prognosis (Figure A.2D). We 
also provided serum from colorectal patients for this study; however, levels of ALCAM 
within the serum did not significantly change in cancer patients when compared to 
normal controls (Figure A.2E) nor did increased expression correlate with stage of 
disease (Figure A.2F). Hansen et al. went on to develop an antibody to detect the 
intercellular domain of ALCAM, and when used with an antibody that detects the 
extracellular domain of ALCAM, it allowed Hansen et al. to define tissues samples which 
showed evidence of shed ALCAM. Upon examining tissue samples from Stage 2 
colorectal cancer cases, they found that ALCAM shedding corresponded with poor 
patient outcome. This suggests that examining ALCAM expression alone may not be 
sufficient to predict patient outcome. 
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Understanding the Role of NFAT in Colorectal Cancer 
 
 
   During my lab tenure, we developed an integrative and comparative 
computational approach to reveal transcriptional regulatory mechanisms underlying 
colon cancer progression in order to understand the mechanism/signaling pathways 
responsible for invasion, migration and metastasis in colorectal cancer. Our lab 
successfully modeled human cancer invasion/metastasis using mouse colon cancer 
cells (MC-38). We have applied this approach to fourteen human colorectal cancer 
(CRC) microarray data sets and to one microarray dataset from an immunocompetent 
mouse model of metastasis, and we have identified known and novel transcriptional 
regulators in CRC. Among these transcriptional regulators, the Nuclear Factor 
of Activated T cells (NFAT) family of transcription factors play a central role in inducible 
gene transcription in various signaling pathways including regulation of cell 
differentiation, development, adaption, immune system response, inflammation, 
adipocyte metabolism, and lipolysis, and carcinogenesis. We then turned to cell culture 
lines to study how the expression of specific NFAT family members alters certain 
biological aspects.  
My focus for this project was the manipulation of NFATc2 in SW480 human CRC 
cell line. Upon depletion of NFATc2 (Figure A.3 D), we note that increased number of 
cells migrated through transwells compared to SW480 that were mock transfected or 
transfected with Scrambled non-targeting siRNA (Figure A.3A,B). We performed parallel 
proliferation studies to show that increased number of cells that were observed on the 
transwell was not due to an increase in proliferation when NFATc2 was knocked down 
(Figure A.3C). Later, in the project our focused shifted away from NFATc2 to NFATc1 as 
NFATc1 was the NFAT family member for which expression changed when MC-38parental 
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cell line is compared MC-38met  cell line (a more highly metastatic derivative cell line) 
(Figure A.4). In data not included in this document, the tumor-associated NFATc1 co-
regulated gene signature was associated with worse clinical survival outcomes in stage 
II colorectal cancer patients. RNAi-based inhibition of NFATc1 expression in the 
MC38met cells resulted in decreased invasiveness in a transendothelial invasion model. 
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Cathepsin B as a Driving Force of Esophageal Cell Invasion 
 
  In 70% of esophageal carcinoma cases, expression of TGFβ Receptor and E-
cadherin is lost (Andl, Fargnoli et al. 2006). We collaborated with the Andl lab in their 
publication in which they found that invasion of esophageal carcinoma was dependent 
upon expression of Cathepsin B (Andl, McCowan et al. 2010). Using an organotypic 
culture model, they utilized TGFβ Receptor and E-cadherin dominant negative 
keratinocytes (EcdnT) and found that EcdnT invaded more so than their E-cadherin and 
TGFβ Receptor expressing counterparts. Examining the differential expression between 
the cell lines, they found that Cathepsin B was up-regulated in the EcdnT cell line.  They 
went on to utilize short hairpin RNA (shRNA) targeting Cathepsin B to knockdown 
expression in the EcdnT cells. Upon depletion of Cathepsin B expression, EcdnT cells 
were less invasive. 
 For our contribution to the study, we aided in the data analysis of 80 tissue core 
samples taken from 40 esophageal carcinoma patients stained for expression of 
Cathepsin B, TGFβ Receptor and E-cadherin (Figure A.5A-D). Specifically, taking the 
data scored by another researcher, we performed the linear regression and showed an 
inverse association in patient samples (Figure A.5E). This finding validated the inverse 
relationship they observed in the EcdnT organotypic model recapitulates an aspect of 
the human esophageal carcinoma.  
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Examining Wnt Signaling in Non-alcoholic Steatohepatitis 
 
  Non-alcoholic Steatohepatitis (NASH) affects some 2-5% of Americans and is 
associated with obesity and diabetes. Previously, research groups have associated Wnt 
signaling with being protective in this disease state as well as other liver ischemia 
models (Lehwald, Tao et al. 2011, Yang, Lee et al. 2014). Charles Flynn, Ph.D. noted a 
specific phospholipid pattern that occurred in his murine NASH model that was 
associated with activated Wnt signaling. To ascertain if there was a mouse model which 
showed localization of activation of Wnt signaling within the liver, he inquired if the Axin2 
reporter mouse with β-galactosidase knocked in to the Axin2 locus would be a suitable 
model system. We collaborated with Dr. Flynn to generate preliminary data investigating 
if the Axin2 mouse would be a suitable model system. To this end, we performed whole 
mount staining on liver isolated from this mouse model and found that β-galactosidase 
activity was detected  surrounding the central veins of the hepatic lobule (Figure 
A.6A,B). The phospholipid pattern Dr. Flynn noted in his NASH model had a similar 
pattern to β-galactosidase staining in the Axin2 mouse suggesting that the Axin2 knock-
in mouse would be suitable to perform  his studies. 
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